Human glioma antigen and process for preparing the same

ABSTRACT

The present invention provides a human glioma antigen or a method for preparing the same, which can be applied to diagnosis and therapy of glioma. A glioma antigen or a glioma antigen gene is prepared by a process comprising the steps of: total RNA is extracted from a glioma cell line and cDNA was synthesized; λ phage cDNA library, which was constructed by infection of  E. coli  caused by introducing said cDNA into λ phage vector, and the sera of glioma patients are made to react; positive clones to which antibodies in the serum reacted are detected with the use of labeled anti-IgG antibodies; screening is repeated several times for the detected positive clones; antigens are isolated from positive clones confirmed to be antibody-reactive; serum screening is conducted by using the isolated antigens, the sera of glioma patients and healthy persons.

TECHNICAL FIELD

[0001] The present invention relates to: a glioma antigen or its gene expressing and showing immunoreaction in a human malignant brain tumor, i.e. glioma; a method for preparing said glioma antigen or its gene; a diagnostic drug for detecting a glioma; a detecting and diagnostic probe; an antibody against a glioma antigen and its gene; a screening method for a promoter or a suppressor for the immunity-inducing activity using a glioma antigen; etc.

BACKGROUND ART

[0002] There has long been expectations on immunotherapies and many attempts have been taken. However, sufficient anti-tumor effects have not been materialized. Cancer immunotherapies have historically been handled with a central focus on the non-specific immunotherapy, however, it has become evident in recent years that a T cell plays an important role at tumor rejection in vivo in human melanoma. Moreover, many efforts have been drawn to the isolation of a T cell recognition tumor antigen which would possibly induce cytotoxic T lymphocyte (CTL) and determining of a MHC Class I-restricted epitope, since when MAGE-1 antigen (Science 254, 1643-7, 1991) was reported by a Belgian group in 1991. The present inventors isolated a CD8+T cell recognition by the cDNA expression cloning method by using a tumor reactive T cell of melanoma (Proc. Natl. Acad. Sci. USA 91, 3515-3519, 1994, Proc. Natl. Acad. Sci. USA 91, 6458-6462, 1994, J. Exp. Med. 180, 347-352, 1994, J. Immunol. 154, 3961-3968, 1995, Immunologic Res. 16, 313-340, 1997), and they reported that an anti-tumor effect was recognized for part of melanoma by this specific immunothoerapy using said antigen (Microbiology Immunology 42, 803-813, 1998, Kawakami, Y., P. F. Robbins, R F. Wang. et al. Identification of Melanoma antigens by T lymphocytes and their use in the immunotherapy of cancer. In Principle and Practice of Oncology. Update. V. DeVita, S. Hellman, S. A. Rosenberg eds. J.B. Lippincott Co. Philadelphia, p1-20, 1996, Nature Med. 4, 321, 1998). It is further found that the antigen recognized by T cell is a peptide bound to a MHC molecule, which is not necessarily derived from a cell surface protein, and intranuclear or cytoplasm protein can be recognized as an antigen (Immunity 10, 281-7, 1999).

[0003] In 1995, groups of Pfreundschuh in Germany and Old et al. in U.S. reported the SEREX method (serological identification of recombinant cDNA expression cloning; Proc. Natl. Acad. Sci. USA 92, 11810-11813, 1995) for detecting cancer antigen protein which is recognized by an IgG antibody in sera of cancer patients. The method is applicable for cancer wherein the establishment of cell line is difficult, and does not necessarily require a tumor and a CTL. Many tumor antigens have been isolated by applying this method, and it has been reported that this method is also effective for detecting antigens recognized by celluler immunity since antigens such as MAGE-1 and tyrosinase which induce CTL were found to be included in the antigens isolated by this method. It is further reported that the cancer antigens recognized by an IgG antibody of a patient was isolated in melanoma, renal cancer, esophageal cancer, colon cancer, lung cancer, etc., by applying the aforementioned method (Int. J. Cancer 72, 965-971, 1997, Cancer Res. 58, 1034-1041, 1998, Int. J. Cancer 29, 652-658, 1998, Int. J. Oncol. 14, 703-708, 1999, Cancer Res. 56, 4766-4772, 1996, Hum. Mol. Genet 6,33-39, 1997). These antigens include important antigens such as a CT (cancer-testis) antigen (SSX2/HOM-MEL-40, NY-ESO-1, SCP-1, CT7 etc.), a differentiated antigen (galectin-4/NY-CO-27), a mutant antigen (p53 etc.). Among these antigens, HLA-A2-restricted epitope is particularly determined with NY-ESO-1. Further, the antigens isolated by the SEREX method include molecules such as e1F-4γ or HER2/neu which over-express in cancer, and which possibly relate to malignant alteration. There is a possibility that these molecules over-expressing in cancer can be applied not only to a therapy but also to a marker for diagnosis or for possibly projecting recurrence and prognosis.

[0004] On the other hand, central nervous system has been known as a venue for immunological tolerance. However, it has recently been appeared that an activated lymphocyte reacts with an intracerebral antigen after transiting through a blood brain barrier and invading into brain (J. Immunol. 158, 2318-26, 1997, J. Neurosci. 18,5804-16,1998). The present inventors further indicated the possibility that a specific immunity-inducing against a tumor antigen in a brain could be a new effective therapy method (Neuro-Oncology 1, S105, 1999). Image analyses by MRI et al. and histopathological analyses by using a specimen obtained through an operation are presently focused on for the diagnostic methods for detecting glioma, malignant brain tumor. However, as the genes related to the generation of glioma are becoming evident due to the progress of molecular cell biology in recent years, the possibility of genetic diagnosis wherein said genes are analyzed is also indicated (Glia. 15, 308-27, 1995).

[0005] At present it is still the case for cancer, which is currently the primary cause of death, that most of advanced cancers cannot be remedied in spite of the improvement in their mechanisms of generation, diagnostic methods, and therapy methods. In particular, malignant brain tumors are extremely difficult to be remedied, and there has been no effective therapy to date in spite of the improvement in brain surgery operations and radiotherapies in recent years. It is required to develop a new and early diagnostic method and a therapy method in order to improve such situation. The object of the present invention is to provide a human glioma antigen which can be applied to diagnosis and therapy of glioma, a gene encoding such antigen, and a method for preparing the same.

[0006] The present inventors have made a keen study to attain the objects mentioned above, and the present inventors constructed cDNA by using mRNA obtained from a glioma cell line, and this cDNA was introduced into λ phage vector to infect Escherichia coli, and by using thus constructed cDNA library (6.0×10⁵ λ phage cDNA clones) derived from a glioma cell line, the present inventors screened the serum of each glioma patient, and found that a glioma antigen which reacts only to the sera of glioma patients and does not react to the sera of healthy persons, and which selectively expresses in cancer cells including a glioma cell line is present, and that an immune system recognizes the protein wherein glioma expresses. Here, the present invention is completed.

DISCLOSURE OF THE INVENTION

[0007] The present invention relates to: a method for preparing a glioma antigen and/or a glioma antigen gene, comprising the following processes, (1) a process of constructing λ phage cDNA library comprising the steps of: total RNA is extracted and purified from a glioma cell line; cDNA is synthesized with the purified mRNA, and this cDNA is introduced into λ phage vector to infect E. coli, (2) a process of generating a reactive serum by eliminating reactants after applying the extract of E. coli to the diluted serum of a glioma patient, (3) a process of detecting positive clones which are reacted by an antibody in the serum by using a labeled anti-IgG antibody after applying the aforementioned λ phage cDNA library to the reactive serum, (4) a process of confirming antibody-reactivity after repeating several screenings for the detected positive clones, (5) a process of a serum screening using the antigens isolated from the positive clones together with at least the sera of glioma patients and healthy persons (claim 1); a diagnostic drug for detecting glioma comprising an antibody which specifically binds to whole or part of one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or glioma antigen genes described in claim 1, and/or to whole or part of said glioma antigens (claim 2); a detecting and diagnostic probe for glioma comprising whole or part of antisense strand of DNA or RNA encoding one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or glioma antigen genes described in claim 1 (claim 3); an anti-tumor agent with an antibody specifically binding to whole or part of one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or a glioma antigen genes described in claim 1, and/or to whole or part of said glioma antigens as an effective ingredient (claim 4).

[0008] The present invention further relates to DNA encoding the following protein (a) or (b), (a) a protein comprising the amino acid sequence shown by SEQ ID NO:2, (b) a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, and which has the immunity-inducing activity (claim 5), DNA comprising the base sequence shown by SEQ ID No:1 or its complementary sequence and part or whole of these sequences (claim 6); DNA which hybridizes under a stringent condition with DNA of claim 6, and which encodes a protein having the immunity-inducing activity (claim 7); DNA encoding the following protein (a) or (b), (a) a protein comprising the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10, (b) a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10, and which has the immunity-inducing activity (claim 8), DNA comprising the base sequence shown by SEQ ID No:3, 5, 7, or 9, or its complementary sequence and part or whole of these sequences (claim 9); DNA which hybridizes under a stringent condition with DNA of claim 9, and which encodes a protein having the immunity-inducing activity (claim 10); DNA encoding the following protein (a) or (b), (a) a protein comprising the amino acid sequence shown by SEQ ID NO:12, (b) a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:12, and which has the immunity-inducing activity (claim 11), DNA comprising the base sequence shown by SEQ ID No:11, or its complementary sequence and part or whole of these sequences (claim 12); DNA which hybridizes under a stringent condition with DNA of claim 12, and which encodes a protein having the immunity-inducing activity (claim 13).

[0009] The present invention still further relates to: a protein comprising the amino acid sequence shown by SEQ ID NO:2 (claim 14); a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, and which has the immunity-inducing activity (claim 15); a protein comprising the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10 (claim 16); and a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO: 4, 6, 8, or 10, and which has the immunity-inducing activity (claim 17); a protein comprising the amino acid sequence shown by SEQ ID NO:12 (claim 18); a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:12, and which has the immunity-inducing activity (claim 19); a peptide comprising a partial protein of any of claims 14 to 19, and which has the immunity-inducing activity (claim 20).

[0010] The present invention also relates to: a fusion protein or a fusion peptide wherein the protein of any of claims 14 to 19 or the peptide of claim 20, and a marker protein and/or a peptide tag, are bound (claim 21); an antibody against the protein of any of claims 14 to 19 or the peptide of claim 20 (claim 22); a host cell comprising an expression system capable of expressing the protein of any of claims 14 to 19 or the peptide of claim 20 (claim 23); a non-human animal whose gene function to encode the protein of any of claims 14 to 19 or the peptide of claim 20 is deficient on its chromosome or which over-expresses the protein of any of claims 14 to 19 or the peptide of claim 20 (claim 24); a screening method for a promoter or a suppressor for the immunity-inducing activity wherein the immunity-inducing activity in T cell is measured and assessed by using the protein of any of claims 14 to 19, the peptide of claim 20, a test substance, and T cell (claim 25).

BRIEF DESCRIPTION OF DRAWINGS

[0011]FIG. 1 is a drawing showing the result of expression analysis of glioma antigen KU-GB-1 by Northern blot method.

[0012]FIG. 2 is a drawing showing the result of expression analysis of glioma antigen KU-GB-2 by RT-PCR.

[0013]FIG. 3 is a drawing showing the result of expression analysis of glioma antigen KU-GB-5 by RT-PCR.

BEST MODE OF CARRYING OUT THE INVENTION

[0014] A method for preparing a glioma antigen and/or a glioma antigen gene of the present invention is not particularly restricted as long as it includes the following processes, (1) a process of constructing λ phage cDNA library comprising the steps of: total RNA is extracted and purified from a glioma cell line; cDNA is synthesized with the purified mRNA, and this cDNA is introduced into λ phage vector to infect E. coli, (2) a process of generating a reactive serum by eliminating reactants after applying the extract of E. coli to the diluted serum of a glioma patient, (3) a process of detecting positive clones which are reacted by an antibody in the serum by using a labeled anti-IgG antibody after applying the aforementioned λ phage cDNA library to the reactive serum, (4) a process of confirming antibody-reactivity after repeating several screenings for the detected positive clones, (5) a process of a serum screening using the antigens isolated from the positive clones together with at least the sera of glioma patients and healthy persons. However, it is preferable to amplify cDNA insert of the positive clone obtained by the process (4) by PCR, and to determine its sequence, and then to conduct homology search with the use of the existing gene data base. Besides, it is preferable to put serum screening in the process (5) not only on the serum of glioma patients and healthy persons, but also on the serum of other brain disease and other cancer patients.

[0015] By way of the aforementioned preparation methods, two groups of antigens i.e. a group of glioma specific antigens (glioma specific antigen genes) reacting only to the sera of glioma patients, and a group of glioma non-specific antigens (glioma non-specific antigen genes) which react to the sera of both glioma and other cancer patients can be obtained. The group of glioma specific antigens (glioma specific antigen genes) is exemplified by novel KU-GB-2, KU-GB-5, L13 together with Cytochrome-C, DEK oncogene, Nuclear Antigen SP100, Sarcolemmal associated protein, KIAA1014 protein, MutL (E. coli) homolog1 (hMLH1) (GenBank Accession No. NM_(—)000249) etc. On the other hand, the group of glioma non-specific antigens (glioma non-specific antigen genes) is exemplified by KU-GB-1, Mitotic centromere associated protein, human S5A (GenBank Accession No.NM_(—)002810, U24704, U51007), or human pUb-R5 (GenBank Accession No.AB033605) as an isoform of human S5A, Minichromosome maintenance deficient-3, etc. Besides, by expressing these glioma antigens either in vivo or in vitro in dendritic cells that are strong antigen-presenting cells, immunity can be induced by injecting these antigen-expressing dendritic cells.

[0016] As for a diagnostic drug for detecting glioma of the present invention, a reagent comprising whole or part of one or more types of glioma antigens obtained by the aforementioned preparation method can be used. Part of glioma antigens can be exemplified by an antigen recognition site and the like of glioma antigens. Or when used in combination of more than one antigen, it is preferable to select from the aforementioned glioma specific antigen group or glioma non-specific group. Besides, as for a diagnostic drug for detecting glioma of the present invention, reagents comprising antibodies such as monoclonal antibodies specifically binding to whole or part of the aforementioned glioma antigens and the like can be used. When said antibodies are used in combination of more than one type, it is preferable to select from the antibodies against the aforementioned glioma specific antigen group or the glioma non-specific antigen group. Examples of diagnostic methods for glioma by using a diagnostic drug for detecting glioma of the present invention include: a method of investigating whether antibody reaction can be acknowledged by applying labeled glioma antigens to an IgG antibody of the serum obtained from a specimen; a method of image diagnosis of glioma of which metes and bounds are indefinite by administering into blood labeled antibodies such as fluorescence or Fe to glioma antigens.

[0017] There is no particular limitation to a detecting and diagnostic probe for detecting glioma of the present invention, as long as such reagent includes whole or part of antisense strand of DNA or RNA encoding one or more types of glioma antigens obtained by the aforementioned method for preparing glioma antigen genes. However, DNA or RNA comprising more than 20 bp is preferable, and it is also preferable to select from antisense strands of DNA or RNA encoding the aforementioned glioma specific antigen group or glioma non-specific antigen group when used in combination of more than one type of probes. A detecting and diagnostic method of glioma using a detecting and diagnostic probe for glioma of the present invention is exemplified by a method of detecting mRNA of the present glioma antigens obtained from a specimen by using a labeling antisense strands. The specific examples of test samples used for detection and diagnosis are genomic DNA, RNA or cDNA that are obtained from the cells of subjects, for example, biopsy such as blood, urine, saliva, tissues, etc., but the test samples will not be limited to these examples.

[0018] As for an anti-tumor agent of the present invention, a formulation comprising whole or part of one or more types of glioma antigens obtained from the aforementioned method for preparing glioma antigens as an effective ingredient can be used. Part of glioma antigen can be exemplified by an antigen recognition site of glioma antigen. And it is preferable to select from the aforementioned glioma specific antigen group or glioma non-specific antigen group when used in combination of more than one type of antigens. A formulation comprising antibodies such as monoclonal antibodies which specifically bind to whole or part of said glioma antigen as an effective ingredient can also be used for anti-tumor agent of the present invention. It is also preferable to select from the antibodies to the aforementioned glioma specific antigen group or glioma non-specific antigen group when more than one type of antibodies are used in combination. When the anti-tumor agents of the present invention are injected orally, intravenously, intradermally, sucutaneously, etc., an anti-tumor effect can be expected due to the increase in the T cell-inducing activity in vivo. Further, T cell can be induced into activated T cell by being stimulated in vitro by using anti-tumor agent of the present invention. For example, tumor reactive activated T cell will be induced when peripheral blood lymphocyte or tumor-infiltrating lymphocyte are stimulated by an anti-tumor agent of the present invention with IL-2, and said activated T cell can be effectively used for adoptive immunotherapy. Genetic therapy wherein genes are selectively introduced into glioma or missile therapy wherein anti-tumor agent is selectively made to act on glioma can be possible by using antibody such as monoclonal antibody of the present invention.

[0019] Proteins as objects of the present invention can be exemplified by novel antigen proteins or their isoforms among the glioma antigens obtained by the aforementioned preparation method of glioma antigens. Examples include: glioma KU-GB-1 comprising the amino acid sequence shown by SEQ ID NO:2; four isoforms of glioma KU-GB-2 i.e. glioma KU-GB-2a comprising the amino acid sequence shown by SEQ ID NO:4; glioma KU-GB-2b comprising the amino acid sequence shown by SEQ ID NO: 6; glioma KU-GB-2c comprising the amino acid sequence shown by SEQ ID NO:8; glioma KU-GB-2d comprising the amino acid sequence shown by SEQ ID NO:10; glioma KU-GB-5 comprising the amino acid sequence shown by SEQ ID NO:12; and a protein which comprises an the amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, 4, 6, 8, 10, or 12 and which has the immunity-inducing activity. The word immunity-inducing activity used herein stands for the activity inducing immunoreaction such as antibody production, cellular immunity, immunological tolerance, and among said immunity-inducing activity, the ones with the T cell inducing activity which increases the frequency of cytotoxic T cell (CTL) precursor cell in peripheral blood is particularly preferable. A peptide of the present invention can be exemplified by a peptide comprising part of said protein and, which has an immunity-inducing activity. Said peptide is not specifically restricted, but can be eligibly exemplified by a peptide comprising recognition site of antibodies, and a recognition site of CD4+ T cell and/or CD8+ T cell. In addition to the aforementioned proteins and peptides as objects of the present invention, recombinant proteins or peptides which specifically bind to antibodies of said proteins and peptides are also included in the present invention, which may collectively be referred to as “the present glioma antigen”. Besides, the origin of the present glioma antigen is not limited to human, and the present glioma antigen is useful for a diagnostic drug for detecting tumor or a screening method for a promoter or a suppressor for the immunity-inducing activity as described hereinafter.

[0020] DNA as an object of the present invention is exemplified by DNA encoding novel antigen proteins among the glioma antigens obtained from the aforementioned method for preparing glioma antigens. The specific examples include: DNA encoding the protein KU-GB-1 comprising the amino acid sequence shown by SEQ ID NO:2; DNA encoding protein KU-GB-2a comprising the amino acid sequence shown by SEQ ID NO:4; DNA encoding protein KU-GB-2b comprising the amino acid sequence shown by SEQ ID NO:6; DNA encoding protein KU-GB-2c comprising the amino acid sequence shown by SEQ ID NO:8; DNA encoding protein KU-GB-2d comprising the amino acid sequence shown by SEQ ID NO:10; DNA encoding protein KU-GB-5 comprising the amino acid sequence shown by SEQ ID NO:12; and DNA encoding a protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, 4, 6, 8, 10, or 12, and which has the immunity-inducing activity, and DNA comprising the base sequence shown by SEQ ID No:1, 3, 5, 7, 9, or 11, or its complementary sequence and part or whole of these sequences.

[0021] Further, DNA encoding a protein of the interest, which has the same effect as glioma antigens such as KU-GB-1, KU-GB-2a, KU-GB-2b, KU-GB-2c, KU-GB-2d, KU-GB-5 etc., having the immunity-inducing activity can be obtained by the hybridization with a DNA library derived from various glioma cells under a stringent condition by using the base sequence shown by SEQ ID NO:1, 3, 5, 7, 9, or 11 or its complimentary sequence and part or whole of these sequences as a probe, and then by the isolation of DNA which hybridize with the probe. DNA obtained hereby is also within the scope of the present invention. A hybridization condition for obtaining the DNA of the present invention is exemplified by hybridization at 42° C., and washing at 42° C. in a buffer solution containing 1×SSC, 0.1% SDS, and more preferable exemplification is hybridization at 65° C. and washing at 65° C. in a washing buffer solution containing 0.1×SSC, 0.1% SDS. There are a number of factors other than the temperature condition mentioned above that affect the hybridization stringency and those skilled in the art can actualize the same stringency as that of the hybridization referred to in the above by appropriately combining various factors.

[0022] Besides, a gene or DNA encoding the present glioma antigen mentioned above, and the present glioma antigen and the like can be used for generating a fusion peptide or a fusion protein wherein the present glioma antigen and a marker protein and/or a peptide tag are bound, an antibody against the present glioma antigen, a host cell comprising expression system capable of expressing the present glioma antigen, a non-human animal whose gene function to encode the present glioma antigens is deficient on its chromosome, or a non-human animal over-expressing the present glioma antigen as specifically described hereinafter.

[0023] Any fusion protein and fusion peptide may be used as a fusion protein and a fusion peptide for the present invention as long as the present glioma antigens bind to marker proteins and/or peptide tags. As for a marker protein, the specific examples include conventionally known ones such as alkaline phosphatase, the Fc region of an antibody, HRP, GFP, etc. Conventionally known peptide tags including His tag, FLAG tag, S tag, etc. are the specific examples of the peptide tags for the use in the present invention. However, there is no limitation to these examples. These fusion proteins can be generated according to the ordinary protocols and are useful for the following: purification of the glioma antigen KU-GB-1, KU-GB-2a, KU-GB-2b, KU-GB-2c, KU-GB-2d, KU-GB-5 or the like using affinity of Ni-NTA and a His tag; detection of a protein having the T cell-inducing activity; quantification of an antibody against the glioma antigen KU-GB-1, KU-GB-2a, KU-GB-2b, KU-GB-2c, KU-GB-2d, KU-GB-5 or the like; as a diagnostic marker for cancer such as glioma and the like; as a laboratory reagent in this field of art.

[0024] An antibody against the present glioma antigen of the present invention can be particularly exemplified by an immune-specific antibody such as a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a single-stranded antibody, a humanized antibody, etc. These antibodies can be generated according to the ordinary protocols by using the present glioma antigen. However, an monoclonal antibody is more preferable than the other sorts of antibodies mentioned above because of its specificity, and particularly, monoclonal antibodies specifically recognizing epitopes such as KU-GB-1, KU-GB-2a, KU-GB-2b, KU-GB-2c, KU-GB-2d, KU-GB-5 etc., or the complex of epitopes and HLA are more preferable. Such monoclonal antibodies or the like are useful not only for diagnosis of cancers such as glioma and missile therapy, but also for elucidating the development mechanism of malignant tumors such as glioma and the like.

[0025] Antibodies of the present invention can be created by administering to an animal (preferably non-human) the present glioma antigen, their fragments containing epitopes, or cells expressing the present glioma antigens, particularly an complex of epitopes and HLA, on the membrane surface, according to the conventional protocols. The monoclonal antibodies can be prepared, for instance, by any optional method such as a hybridoma method that brings antibodies produced by cultured materials of continuous cell line (Nature 256, 495-497, 1975), a trioma method, a human B-cell hybridoma method (Immunology Today 4, 72, 1983), and an EBV-hybridoma method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp.77-96, Alan R. Liss, Inc., 1985), etc.

[0026] The method for preparing a single chain antibody (U.S. Pat. No. 4,946,778) can be adopted to prepare single-stranded antibodies to the present glioma antigens of the present invention mentioned above. Besides, transgenic mice, other mammals, etc. can be used for expressing humanized antibodies, clones expressing the present glioma antigens can be isolated/identified using the antibodies mentioned above, and their polypeptides can be purified by affinity chromatography. Antibodies to the present glioma antigens or to their peptides containing antigenic epitopes can possibly be used for diagnosis and therapy for glioma etc. Furthermore, recombinant proteins or peptides to which these antibodies specifically bind are also covered by the present glioma antigens of the present invention as described earlier.

[0027] A host cell comprising an expression system capable of expressing the present glioma antigens can be constructed by introducing genes encoding the present glioma antigens into the host cell, by the methods described in many standard laboratory manuals such as manuals of Davis et al. (BASIC METHODS IN MOLECULAR BIOLOGY, 1986) and of Sambrook et al. (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and the specific examples include calcium-phosphate transfection, DEAE-dextran-mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection, etc.

[0028] The examples of host cells mentioned above include bacterial prokaryotic cells such as E. coli, Streptomyces, Bacillus Subtilis, Streptococcus, Staphylococcus, etc., eukaryotic cells such as yeast, aspergillus, etc., insect cells such as Drosophila S2, Spodoptera Sf9, etc., animal cells such as L cell, CHO cell, COS cell, HeLa cell, C127 cell, BALB/c3T3 cell (including mutants deficient in dihydrofolate reductase, tymidine kinase, etc.), BHK21 cell, HEK293 cell, and plant cells or the like. Further, a host cell having a HLA-expressing ability, and which comprises an expression system capable of expressing the present glioma antigen can be generated by introducing a gene encoding the present glioma antigen into a host cell having a HLA-expressing ability or a host cell not originally having said ability to those which HLAcDNA was transfected according to the aforementioned methods.

[0029] There is no limitation to an expression system as long as the expression system is capable of expressing the present glioma antigens described above in a host cell and the examples include chromosome-, episome- and virus-derived expression systems, for instance, vectors derived from bacterial plasmid, vectors derived yeast plasmid, vectors derived papovavirus such as SV40, vaccinia virus, adenovirus, adeno-associated virus, chicken pox virus, pseudorabies virus, retrovirus, and vectors derived bacteriophage or transposon and vectors derived the combination of these two, e.g. vectors derived from genetic factors of plasmid and bacteriophage, such as cosmid and phagemid. The expression systems may comprise a control sequence for regulating the expression in addition to a sequence for raising the expression.

[0030] Host cells comprising the above-mentioned expression systems and the cell membranes of the cells, or the present glioma antigens obtained by culturing the cells can be used in the screening methods of the present invention as described below. For example, the method of F. Pietri-Rouxel et al. (Eur. J. Biochem., 247, 1174-1179, 1997) or the like can be used to obtain cell membranes. Further, to collect and purify the present glioma antigens from the cell culture, the known methods can be adopted including ammonium sulfate- or ethanol-precipitation, acid extraction, anion- or cation-exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography and lectin chromatography, where the high performance liquid chromatography is preferably used. As a column especially used for affinity chromatography, columns to which antibodies to the present glioma antigens are bound, for instance, are used, and when ordinary peptide tags are added to the present glioma antigens mentioned above, columns to which substances having affinity with the peptide tags are bound are used in order to obtain the present glioma antigens.

[0031] A non-human animal whose gene function to encode the present glioma antigens of the present invention is deficient on its chromosome means a non-human animal part or whole of whose gene on its chromosome encoding the present glioma antigens is inactivated by gene mutations such as disruption, deletion, replacement, etc., so that whose function to express the present glioma antigens is lost. Further, a non-human animal which over-expresses the present glioma antigens is specifically exemplified by a non-human animal which produces larger amount of the present glioma antigens than a wild-type non-human animal does. Although rodents or the like such as mice, rats, etc. are particularly exemplified for non-human animals of the present invention, the examples will not be limited to these animals only.

[0032] Homozygous non-human animals that are born according to Mendel's Law include the deficient type or the over-expressing type for the present glioma antigens as well as their wild type littermates. By using the deficient type animals or the over-expressing type animals of these homozygous non-human animals together with their wild-type littermates at the same time, accurate comparative experiments can be carried out on the individual level. In performing screening of the present invention described below, it is, therefore, preferable to use the wild type non-human animals, i.e. animals of the same species as, or even better the littermates of, non-human animals whose gene function to encode the present glioma antigens is deficient or over-expressing on their chromosomes in parallel with the deficient or over-expressing type animals. The method of producing a non-human animal whose gene function to encode the present glioma antigens is deficient or over-expressing on its chromosome is now explained in the following with the present glioma antigen knockout mouse and the present glioma antigen transgenic mouse.

[0033] A mouse, for instance, whose gene function to encode the present glioma antigen is deficient on its chromosome i.e. the present glioma antigen knockout mouse is generated by the following steps. A gene encoding the present glioma antigen is screened by using a gene fragment obtained by a method such as PCR or the like from the mouse gene library. A screened gene which encodes the present glioma antigens is subcloned with a viral vector or the like and is identified by DNA sequencing. Then whole or part of a gene of this clone which encodes the present glioma antigen is substituted with a pMC1 neo gene cassette or the like. A gene such as a diphtheria toxin A fragment (DT-A) gene, a herpes simplex virus tymidine kinase (HSV-tk) gene, etc. is introduced onto the 3′-end, and thus a targeting vector is constructed.

[0034] The targeting vectors thus constructed are linearlized and introduced into ES cells by electroporation or the like to cause homologous recombination. Among the homologous recombinants, ES cells in which homologous recombination have occurred are selected by the use of antibiotics such as G418, ganciclovir (GANC), etc. It is preferable to confirm whether the selected ES cells are the recombinants of the interest by Southern blotting or the like. A clone of the ES cells confirmed is microinjected into a mouse blastocyst and which blastocyst is placed back to the recipient mouse to generate a chimeric mouse. A heterozygous mouse can be obtained by intercrossing the chimeric mouse and a wild type mouse. By further intercrossing the heterozygous mice, the present glioma antigen knockout mice of the present invention can be generated. Whether the present glioma antigens knockout mouse is generated is examined by Northern blotting upon isolating RNA from the mouse obtained by the above-described method and by Western blotting or the like with which the expression of the mouse can be directly examined.

[0035] The present glioma antigen transgenic mouse is created by the following steps. A promoter such as chicken β-actin, mouse neurofilament, SV40, etc. and poly (A) such as rabbit β-globin, SV40, etc. or introns are fused with cDNA encoding the present glioma antigen to generate a transgene. This transgene is microinjected into the pronucleus of a mouse fertilized egg. After the obtained egg cell is cultured, it is transplanted to the oviduct of the recipient mouse which was fed thereafter. Neonetal mice that have the aforementioned cDNA were selected from among all the mice born and thus the transgenic mice are created. Neonatal mice having the cDNA can be selected by extracting crude DNA from the mice tails or the like and then by a dot hybridization method using a gene encoding the introduced present glioma antigen as a probe and by PCR method or the like using a specific primer.

[0036] As for a screening method for a promoter or a suppressor for the immunity-inducing activity of the present invention, it is not specifically restricted as long as the method comprises the measurement and assessment of the immunity-inducing activity of T cell by using the present glioma antigen, a test substance, and T cell. Examples include methods wherein immunity-inducing activity in said T cell is measured and assessed by using the following: a test substance, the present glioma antigen, and T cell; a test substance, a cell membrane or a cell which expresses the present glioma antigens, and T cell; T cell and a host cell expressing the present glioma antigens and to which vectors expressing HLA are transfected together with vectors expressing a test polypeptide; T cell and a host cell expressing the present glioma antigens which has a HLA-expressing ability and which is transfected with vectors expressing a test polypeptide, and a method wherein immunity-inducing activity in a T cell is measured and assessed on non-human animals by administering a test substance to said non-human animals such as the aforementioned knock-out mice and transgenic mice. Specific examples of the aforementioned cell membrane or a cell include: the primarily cultured cells or the like obtained from non-human animals wherein a gene encoding the present glioma antigen is over-expressing, or wild type of non-human animals; a host cell comprising an expression system capable of expressing the aforementioned present glioma antigens; cell membrane of these cells. The method of contacting a cell membrane or cell and a test substance is exemplified by a method wherein a cell membrane or a cell which expresses the present glioma antigen is cultured in vitro under the presence of a test substance, and subsequently contacted with T cell. A method wherein immunity-inducing activity in a T cell is measured and assessed can be specifically exemplified by a method of measuring which has an amount of IFN r released from T cell onto culture media as an indicator. Further, a promoter for the immunity-inducing activity obtained by the aforementioned screening method can be applied to the therapy for patients in need of the promotion of immunity-inducing activity. Meanwhile, a suppressor for the immunity-inducing activity can be applied to the therapy for patients in need of the suppression of the immunity-inducing activity.

[0037] The present invention will be further specifically explained in the following with reference to the examples, but the technical scope of the invention will not be limited to these examples.

Cell Lines and Tissues

[0038] Human glioma cell line (GI-1, T98G, U87MG, U251), human malignant melanoma cell line (SKmel23, 1362mel, 888mel), lung cancer cell line (LU99, RERF-LC-MA, EBC1), esophageal cancer cell line (TE10), breast cancer cell line (MDA231), pancreatic cancer cell line (PK1), renal cell carcinoma cell line (RCC6), bladder carcinoma cell line (BC47), prostate cancer cell line (PC3), leukemia cell line (HL60, Molt4) are cultured in RPMI comprising 10% of a fetal bovine serum to which penicillin (100 IU/ml) and streptomycin (100 μg/ml) is added respectively. Pancreatic cancer cell line (KU7) was cultured in RPMI1640 comprising 10% of a fetal bovine serum to which penicillin/streptomycin (1%), L-glutamine (1%), HEPES (10 mM), EGF (6 μg/l), insulin (150 U/l), hydrocortisone (0.5 mg/l), transferrin (10 mg/l) are added. Part of lesion extirpated during an operation was applied to a human glioma tissue (GB13, GB16, GB17, GB4). Total RNA of normal tissues (brain, heart, lung, stomach, colon, liver, spleen, small intestine, renal, testis, placenta, muscle, embryonic brain) were purchased from Clontech.

Generating of cDNA Library

[0039] Total RNA was isolated from the aforementioned glioma cell line U87-MG and T98G by the cecium chloride ultracentrifuge method. After mixing 1 mg of each cell line, mRNA was purified by way of poly (A) selection using oligotex (dT) 30 (TAKARA). cDNA was synthesized by reverse transcription by using ZAP-cDNA Synthesis Kit (Stratagene) from 5 μg of purified mRNA. A phage cDNA library was constructed by incorporating said cDNA into A ZAP expressing phagemid vector.

Serum Screening of cDNA Library

[0040] The cDNA library constructed as above is sprayed onto 150 mm NZY agarose plate by 1×10⁴ clone, and cultured at 42° C. for 4 hours, and then at 37° C. for 4 hours. Thereafter, recombinant protein of which expression was induced by 10 mM of IPTG on E. coli (XL1-Bllue) was transcribed onto nitro cellulose filter (Hybond-c, Amersham, Buckinghamshire, England). After adsorbed bacteria or phage are removed by washing the filter with TBS comprising 0.05% of TWIN20 (10 mM Tris-HCl, 150 mM Nacl; pH7.5), non-specific reaction was suppressed by TBS comprising 5% of skimmed milk. This filter was applied to a patient's serum which had been diluted for 100 times or 400 times at 37° C. for 4 hours. As for the sera of patients, the ones collected from 12 glioma patients as shown in Table 1, and the ones collected from 8 glioma patients as shown in Table 2 and combined with the sera of 4 glioma patients [(the sera of the patients G20, G21, G22, G27 were combined), (the sera of the patients G18, G23, G24, G28 were combined)] were applied. These sera were preserved at −80° C., and diluted five times with TBS solution comprising 5% of skimmed milk immediately prior to be used. These sera were further combined with lysate of bacteriolysed E. coli at 1:2 and reacted at 4° C. for 8 hours in order to precedently remove the antibody which reacts to bacteria. Its supernatant was ultimately diluted for 100 times (as for the cases of sera of patients shown in Table 1 was used) or 400 times (as for the cases of sera of 4 patients shown in Table 2 was used.). TABLE 1 Patients' positive different serum age sex diagnosis clones inserts G 48 M Glioblastoma 5 4 H 77 F Anaplastic 4 4 oligoastrocytoma I 53 F Glioblastoma 3 2 K 26 F Glioblastoma 18 8 L 61 M Anaplastic 15 5 oligoastrocytoma N 32 F Anaplastic 9 7 astrocytoma O 62 F Glioblastoma 1 1 P 30 M Anaplastic 6 3 astrocytoma R 53 F Glioblastoma 18 12 S 49 F Astrocytoma 8 2 U 61 F Glioblastoma 1 1 V 68 F Glioblastoma 4 3 total 92 52

[0041] TABLE 2 types of Patients positive isolated serum age sex diagnosis clones genes G20 17 F Anaplastic Astrocytoma G21 32 M Astrocytoma G22 18 M Astrocytoma {close oversize bracket}  4 {close oversize bracket} 3 Anaplastic G27 25 M Astrocytoma G18 21 F Glioblastoma 5 G23 3 F Astrocytoma (incl. G24 7 F Oligoastrocytoma {close oversize bracket} 17 {close oversize bracket} a G28 41 M Anaplastic novel oligoastrocytoma type) Total 21 8

[0042] Said processed serum was reacted to recombinant protein blotted onto nitro cellulose filter at 37° C. for 4 hours, and then recombinant protein which was reacted by antibodies within a serum was detected by using alkaline phosphatase-labeled anti-human IgG antibody (ICN Pharmaceuticals). Thereafter, positive clones which coincide with coloring reactive positive site was recovered from the aforementioned 150 mm NZY agarose plate and dissolved into SM buffering solution (100 mM of NaCl, 10 mM of MgSO₄, 50 mM of Tris-HCl, 0.01% of gelatin; ph7.5). This screening was further conducted for several times, and thus antibody reactivity of the positive clones was confirmed. As a result of the screening from 5×10⁵ phage clones per serum of one patient, 92 positive clones from the patients' sera shown in Table 1 and 21 positive clones from the patient' sera shown in Table 2 were isolated. Number of isolated positive clones by each patient are shown in Table 1 and 2. Among the 92 positive clones obtained from the patients' sera shown in Table 1, 18 clones were obtained from the patient K of Glioblastoma, 18 clones were from the patient R of Glioblastoma, and 15 clones were from the patient L of Anaplastic oligoastrocytoma. Herein a tendency wherein positive clones are concentrated to the specific patients' sera was acknowledged, however, this tendency appeared to have no apparent relationship with patients' age or malignancy.

Homology Search of Isolated Antigen Gene

[0043] cDNA inserts which were integrated into 92 phages obtained by using the patients' sera shown in Table 1 and 21 phages obtained by using the patients' sera shown in Table 2 were amplified by PCR method and each base sequence was determined. ExTaq (TAKARA) was used as a reactive enzyme, T3 (5′-AATTAACCCTCACTAAAGGG-3′; SEQ ID NO:13) was used as a sense primer, and T7 (5′-GTAATACGACTCACTATAGGGC-3′ SEQ ID NO:14) was used as an anti-sense primer. Reaction condition was as follows: a cycle of denaturation for 5 minutes at 94° C. at the beginning only by using thermal cycler (Perkin Elmer), followed by thermal denaturation for one minute at 94° C., annealing for 1 minute at 55° C., and extension for 2 minutes at 72° C. was repeated 35 times, and extension for 7 minutes at 72° C. was conducted lastly. Approximately 300-500 bp of the base sequence on 5′ end were determined by DNA sequencing of the PCR products obtained herein with applications of Big Dye DNA Sequencing Kit (ABI) and ABI310 auto sequencer. The DNA determined herein was compared with gene information registered in the gene data base of National Center for Biotechnology Information or EST data base, and homology to the existing genes was searched. As a result, 92 positive clones obtained by using patients' sera shown in Table 1 were turned out to be 52 types of antigen cDNA comprising cDNA encoding 38 types of known proteins and cDNA encoding 14 types of new proteins. The number of 52 types of antigen cDNA present in each patient is shown in Table 1. Further, 21 positive clones obtained by using patients' sera shown in Table 2 were turned out to be 8 types of antigen cDNA comprising cDNA encoding 7 types of known proteins and cDNA encoding 1 type of new protein. The number of 8 types of antigen cDNA present in each patient is shown in Table 2.

Serum Screening

[0044] In order to consider the application to a serum diagnosis of glioma by using each clone expressing 52 types of antigens isolated by using patients' sera as shown in Table 1, screening of each serum which was diluted for 100 times of the following was raised: 17 glioma patients (Glioblastoma 9, Anaplastic astrocytoma 5, Anaplastic oligoastrocytoma 2, diffuse Astrocytoma 1); for part of antigens, 29 glioma patients (Glioblastoma 12, Anaplastic astrocytoma 7, Anaplastic oligoastrocytoma 4, Astrocytoma 4, Oligoastrocytoma 2); 8 patients of other brain deseases (malignant lymphoma 2, brain abscess 1, meningioma 3, metastatic glioma 1, subarachnoid bleeding 1); 16 patients of other cancer (malignant melanoma 4, pancreatic cancer 4, renal cancer 4, esophageal cancer 4); and 16 healthy persons (26 persons or 54 persons for a part of antigens). It was investigated whether IgG antibody against each isolated glioma antigen can be detected in these sera. As a result, the following antigens were obtained: 7 types of glioma-specific antigens (glioma specific antigen genes) which react exclusively with the sera of glioma patients; 4 types of glioma non-specific antigens (glioma non-specific antigen genes) which react with the sera of glioma patients and patients of other cancers but do not react with sera of other healthy persons. 7 types of glioma specific antigens (glioma specific antigen genes) included Cytochrome-C, DEK oncogene, Nuclear Antigen SP100, Sarcolemmal associated protein, K1AA1014 protein in addition to the novel KU-GB-2, L13 as shown in Table 3. Besides, 4 types of glioma non-specific antigens (glioma non-specific antigen genes) included Mitotic centromere associated protein, human S5A, Minichromosome maintenance deficient-3, in addition to the novel KU-GB-1 as shown in Table 4. The sera of cancer patients other than glioma which react to said glioma non-specific antigens are as follow; melanoma and renal cancer patients' sera for KU-GB-1, pancreatic cancer patients' sera for Mitotic centromere associated protein, esophageal cancer patients' sera for human S5a, melanoma patients' sera for Minichromosome maintenance deficient-3. TABLE 3 Patients of Patients Other of Antigens Glioma Healthy Brain other (Antigen genes) Patients Persons Diseases cancers KU-GB-2 5/29 0/54 0/8 0/16 L13 2/17 0/16 0/8 0/16 Cytochrome-C 1/17 0/16 0/8 0/16 DEK oncogene 1/17 0/16 0/8 0/16 Nuclear Antigen SP100 1/17 0/16 0/8 0/16 Sarcolemmal 1/17 0/16 0/8 0/16 associated protein KIAA1014 protein 1/17 0/16 0/8 0/16

[0045] TABLE 4 Patients of Patients Other of Antigens Glioma Healthy Brain other (Antigen genes) Patients Persons Diseases cancers KU-GB-1 1/29 0/54 0/8 2/16 Mitotic centromere 2/17 0/16 0/8 1/16 associated protein human S5a 3/17 0/26 0/8 1/16 Minichromosome 1/17 0/16 0/4 1/16 maintenance deficient-3

[0046] The aforementioned 7 types of glioma specific antigens and 4 types of glioma non-specific antigens are considered to be effective as serum diagnosis products or therapy products for glioma or cancer including glioma, since they do not show an antibody reaction against the sera of other brain disease patients or healthy persons. For example, as in the result of detecting the aforementioned IgG antibody, antibody reaction against human S5a was found in the sera of glioma patients and esophageal cancer patients, but no reaction was found in the sera of other brain disease patients and healthy persons. Therefore, human S5a is considered to be effective as serum diagnosis products or therapy products for cancers including glioma. In addition, this human S5a is registered by 3 types of the names to GenBank [Human proteasome 26S subunit, non-ATPase 4 (PSMD4): Accession No.NM_(—)002810, Antisecretory factory 1: Accession No.U24704, 26S protease subunit S5a:Accession No.U51007]. It is reported (EMBO J.19, 4144-4153, 2000) that one type of isoform showing neuro-specific expression is present in this human S5a. There is a high possibility that this isoform i.e. human pUb-R5 (Accession NO.AB033605) is also a glioma antigen as human S5a.

[0047] In order to consider the application to serum diagnosis of glioma by using each clone expressing 8 types of antigens isolated by using patients' sera as shown in Table 2, screenings for each serum diluted for 100 times of the following were raised: 29 glioma patients (Glioblastoma 12, Anaplastic astrocytoma 7, Anaplastic oligoastrocytoma 4, Astrocytoma 4, Oligoastrocytoma 2); 14 patients of other brain disease (malignant lymphoma 2, brain abscess 1, subarachnoid bleeding 1, Parkinson's disease 2, meningioma 4, neurocytoma 1, craniopharyngioma 1, metastatic brain tumor 2); and 37 healthy persons. It was investigated whether IgG antibody against each isolated antigen can be detected in these sera in a manner similar to the aforementioned. As a result, 2 types of glioma-specific antigens (glioma specific antigen genes) were found, one of which reacts exclusively with the sera of glioma patients, and the other one of which reacts with most of the sera of glioma patients but showed little reaction with the sera of healthy persons. These 2 types of glioma specific antigens (glioma specific antigen genes) were found to be a novel KU-GB-5 and MutL as shown in Table 5 (E. coli) homolog1 (hMLH1) (GenBank Accession No.NM_(—)000249). The aforementioned 2 types of glioma-specific antigens are considered to be effective as glioma serum diagnosis products or therapy products because these antigens react specifically with the sera of glioma patients or with the sera of most of glioma patients. TABLE 5 Serum Screening GeneBank Patients of Accession Glioma Healthy Other Brain Genes NO. Patients Persons Disease KU-GB-5 None 1/29 0/37 0/14 MutL NM000249 5/29 1/37 0/14 (E. coli) homolog1 (hMLH1)

Determination of Base Sequence and the Amino Acid Sequence of Antigens

[0048] As a result of investigating the base sequence of isolated clones by using the automatic DNA sequencer (ALF Express, Pharmacia Biotech), it was found that KU-GB-1 consisted of the base sequence (SEQ ID NO:1) with the full length of 3709 bp comprising the genes encoding 1120 amino acid sequences (SEQ ID NO: 2). On the contrary, it was found that 4 types of isoforms are present in KU-GB-2. Namely, KU-GB-2a which consists of the base sequence (SEQ ID NO: 3) with the full length of 3533 bp comprising the genes encoding 1154 amino acid sequences (SEQ ID NO:4), together with 3 types of isoforms i.e. KU-GB-2b, KU-GB-2c, and Ku-GB-2d were found. The base sequence and the amino acid sequence of KU-GB-2b are shown respectively in SEQ ID NOS:5 and 6, the base sequence and the amino acid sequence of KU-GB-2c are shown respectively in SEQ ID NOS:7 and 8, the base sequence and the amino acid sequence of KU-GB-2d are shown respectively in SEQ ID NO:9 and 10. It was further found that KU-GB-5 consists of the base sequence (SEQ ID NO:11) with the full length of 3847 bp comprising the genes encoding 891 amino acid sequences (SEQ ID NO:12).

Northern Blot Method for Detecting the mRNA Expression of Glioma Antigens

[0049] Northern Blot was conducted for KU-GB-1 by using RNA derived from normal tissues (brain, heart, kidney, spleen, liver, small intestine, lung, testis, placenta, stomach, RNA derived from human glioma cell line (GI-1, U87-MG, T98G), or human glioma tissues (GB13, GB17), RNA derived from the following cell lines: human malignant melanoma cell line (1362mel, 888mel); lung cancer cell line (LU99, RERF-LC-MA); esophageal cancer cell line (TE10); breast cancer cell line (MDA231); pancreatic cancer cell line (PK1); renal cell carcinoma cell line (RCC6); bladder carcinoma cell line (BC47); prostate cancer cell line (PC3); and leukemia cell line (HL60, Molt4). RNA (11 μg each) was electrophoresed in agarose gel comprising formamid NOe and formaldehyde, and removed into nylon membrane filter (Hybond XL, Amersham).

[0050] Secondly, a gene fragment comprising KU-GB-1 with the full length of 3709 bp was labeled with ³²P as a probe by using High Prime DNA Labeling Kit (Boehringer). Nylon membrane filter was soaked in Quick Hyb (Stratagene) which is used as hyblidization buffer. Pre-hyblidization was conducted at 68° C. for 30 minutes. Thereafter, hyblidization was conducted at 68° C. for 2 hours in the Quick hyb to which the aforementioned probe was added. And then, said hyblidized nylon membrane filter was washed with the lavage fluid I (2×SSC, 0.1% of SDS) at the room temperature for 15 minutes for two times, and then with the lavage fluid II (0.1×SSC, 0.1% of SDS) at 68° C. for 15 minutes for two times. Detecting for radioactive signal was conducted with the washed nylon membrane filter by using Molecular Imager (BIORAD), of which result is shown in FIG. 1.

[0051] As shown in FIG. 1, gene expression of KU-GB-1 in the normal tissues was not found except in testis, but high-level expression was found only in the cancer cell lines including glioma. Therefore, KU-GB-1 gene is considered to be effective as genetic diagnosis products for cancer including glioma. Further, as described above, having considered the fact that antibody reaction against KU-GB-1 antigens was acknowledged with the sera of glioma and other cancer (malignant melanoma, renal cancer) patients, but no antibody reaction against other brain disease patients or healthy persons was acknowledged, KU-GB-1 antigens are considered to be effective as diagnostic drugs or therapy products for cancer including glioma. Regarding the expression in testis, there is considered to be little possibility that a damage of testis could be a problem when KU-GB-1 antigen is practically used for immunotherapy and the like since this tissue is insulated from immune-system.

RT-PCR Method for Detecting the Expression of Glioma Antigens

[0052] Subsequently, the expression specificity of glioma antigens KU-GB-2 genes or KU-GB-5 genes were investigated by the RT-PCR method in each normal tissue, glioma cell lines and tissues, and other tumor cell lines. A panel of cDNA as a template of RT-PCR was generated in total reaction amount of 200μl at 42° C. by using each 5 μg of RNA derived from the following; normal tissues such as brain, heart, lung, stomach, liver, pancrea, small intestine, kidney, placenta, testis, colon, muscle, embryonic brain (purchased exclusively from Clontech), 4 types of glioma cell lines (GI-1, U251, U87MG, and T98G), 4 types of glioma tissues (GB13, GB16, GB17, GB4), cell lines such as malignant melanoma cell line (Skmel23), lung cancer cell line (LU99, EBC1), esophageal cancer cell line (TE10), pancreatic cancer cell line (KU7), breast cancer cell line (MDA231), and leukemia cell line (Molt4), and a avian myeloblastosis virus reverse transcriptase (TAKARA) and oligo (dT) as a primer.

[0053] For detecting KU-GB-2, (5′-AGAGCGACCTTGAGACCAGAAA-3′; SEQ ID NO:15) was used as a sense primer, and (5′-ACACAAGGCAGGAGATGGAAGT-3′; SEQ ID NO:16) was used as an anti-sense primer. For detecting KU-GB-5, (5′-AAAACTCGCCTTTCTGAACC-3′; SEQ ID NO:17) was used as a sense primer, and (5′-AGCAAGTAACTGGAGAAGCA-3′; SEQ ID NO: 18) was used as an anti-sense primer. For detecting β actin (c551 bp) as a control, (5′-GTCGACAACGCATCCGGCATGTGCA-3′; SEQ ID NO:19) was used as a sense primer, and (5′-GGATCTTCATGAGGTAGTCAGTCAG-3′; SEQ ID NO:20) was used as an anti-sense primer. A cycle wherein a thermal denaturation is conducted at 94° C. for one minute by using these PCR primers, EXTaq (TAKARA) as a reactive enzyme, and thermal cycler (Perkin-Elmer), and stretch reacting is held at 72° C. for one minute after annealing was repeated for 30 times. Annealing temperature was set at Tm of the primers [62° C. for KU-GB-2, 60° C. for KU-GB-5, 68° C. for β actin as a control], and conducted for 1 minute (30 seconds for KU-GB-5). PCR products obtained herein was electrophoresed in agarose gel (2.0%), and stained by ethidium bromide (EtBr), and then band was detected by ultraviolet irradiation. A result of RT-PCR for KU-GB-2 is shown in FIG. 2, and a result of RT-PCR for KU-GB-5 is shown in FIG. 3 respectively. As shown in FIG. 2, strong expression of KU-GB-2 was found in U87-MG, GI-1 (human glioma cell line), GB13, GB17 (glioma tissue), Skmel23 (malignant melanoma cell line), and testis. Expression was weak in U251 (human glioma cell line), LU99 (lung cancer cell line), brain, small intestine, and stomach. Further, two bands are acknowledged in FIG. 2. But as mentioned above, 4 types of isoforms are present in KU-GB-2, of which bigger bands (top lane; 628 bp) show the expression of KU-GB-2b and KU-GB-2d, and smaller bands (bottom lane; 4476 bp) show the expression of KU-GB-2a and KU-GB-2c. And FIG. 3 shows that the strong expression of KU-GB-5 was acknowledged in GI-1, U251 (human glioma cell line), GB13, GB17 (glioma cell line), and testis, and weak expression can be seen in U87MG (human glioma cell line), GB16 (glioma tissue), brain, lung, spleen, and embryonic brain.

[0054] As shown in FIGS. 2 and 3, the high-level expression of genes cannot be seen in the normal tissues except for testis but only in glioma or Skmel 23 (malignant melanoma cell line) with KU-GB-2 and KU-GB-5 as is the case with KU-GB-1. Further, RT-PCR analysis was conducted respectively for 4 types of isoform which are present in KU-GB-2 as aforementioned, and as a result, it appeared that KU-GB-2a and KU-GB-2b show a expression pattern which is specific to nervous systems. Judging from these factors, individual genes belong to KU-GB-1 gene are also considered to be effective as genetic diagnosis products for cancer including glioma. Further, as described above, having considered the fact that antibody reaction against KU-GB-2 antigens was acknowledged specifically with the sera of glioma patients but not with the sera of other cancers and other brain disease patients or healthy persons, KU-GB-2 antigens are considered to be effective as diagnostic drugs or therapy products for glioma. And KU-GB-5 antigens are considered to be effective as serum diagnosis products or therapy products for glioma since they specifically react with the sera of glioma patients. Regarding for the expression in testis, there considered to be little possibility that impaired testis could be a problem when KU-GB-2 antigens or KU-GB-5 antigens are practically used for immunotherapy since testis is a tissue which is insulated from immune system.

Industrial Applicability

[0055] A glioma antigen or a glioma antigen gene DNA obtained by a method for preparing a glioma antigen and/or a glioma antigen gene of the present invention is effective as for therapy and diagnosis of cancers such as glioma and the like, and for obtaining the basic knowledge of sideration of glioma.

1 20 1 3709 DNA Homo sapiens CDS (170)..(3532) 1 ggcacgagtc tatctcatca ataaacattc actgggttct tggtttaagg ggtttgagaa 60 gcttgccacc tcccagcgtt tattattatt tttttctttt gccccgacct ttagcctctg 120 ggccatttgt aatacatatt taatttttag tcacaggaaa taagtaatc atg gtg ctc 178 Met Val Leu 1 aac agt ttg gat aag atg att caa ctc cag aaa aac act gcc aac atc 226 Asn Ser Leu Asp Lys Met Ile Gln Leu Gln Lys Asn Thr Ala Asn Ile 5 10 15 agg aat att tgt gtt ttg gct cat gtt gac cat gga aaa act act ctg 274 Arg Asn Ile Cys Val Leu Ala His Val Asp His Gly Lys Thr Thr Leu 20 25 30 35 gct gac tgt ctt ata tct agc aat gga atc atc tcc agc cgc cta gca 322 Ala Asp Cys Leu Ile Ser Ser Asn Gly Ile Ile Ser Ser Arg Leu Ala 40 45 50 ggc aag tta agg tac atg gac agc aga gaa gat gaa cag atc cga ggg 370 Gly Lys Leu Arg Tyr Met Asp Ser Arg Glu Asp Glu Gln Ile Arg Gly 55 60 65 atc act atg aaa tcc agt gcc att tcc cta cat tat gca aca ggt aat 418 Ile Thr Met Lys Ser Ser Ala Ile Ser Leu His Tyr Ala Thr Gly Asn 70 75 80 gag gag tac ctg atc aat ctg ata gac tct cca gga cac gtg gac ttt 466 Glu Glu Tyr Leu Ile Asn Leu Ile Asp Ser Pro Gly His Val Asp Phe 85 90 95 tcc tca gaa gta tca acc gct gtt cgc att tgt gat gga tgc atc att 514 Ser Ser Glu Val Ser Thr Ala Val Arg Ile Cys Asp Gly Cys Ile Ile 100 105 110 115 gtg gta gat gct gtg gaa gga gtc tgt cca cag aca cag gca gtt ctg 562 Val Val Asp Ala Val Glu Gly Val Cys Pro Gln Thr Gln Ala Val Leu 120 125 130 cga caa gct tgg ctt gaa aac atc cgt ccg gtt tta gtg att aat aag 610 Arg Gln Ala Trp Leu Glu Asn Ile Arg Pro Val Leu Val Ile Asn Lys 135 140 145 att gat cgc ttg ata gtg gaa ctg aaa ttc acc cca caa gag gcc tat 658 Ile Asp Arg Leu Ile Val Glu Leu Lys Phe Thr Pro Gln Glu Ala Tyr 150 155 160 tct cac ctc aag aat att tta gaa cag att aat gcg ctc aca ggg act 706 Ser His Leu Lys Asn Ile Leu Glu Gln Ile Asn Ala Leu Thr Gly Thr 165 170 175 ctt ttt act tct aaa gtc cta gaa gaa aga gca gag agg gag act gaa 754 Leu Phe Thr Ser Lys Val Leu Glu Glu Arg Ala Glu Arg Glu Thr Glu 180 185 190 195 tcc caa gtg aat cca aat tct gaa caa gga gag caa gta tat gac tgg 802 Ser Gln Val Asn Pro Asn Ser Glu Gln Gly Glu Gln Val Tyr Asp Trp 200 205 210 agc act ggc ttg gag gac aca gat gat tct cac ctt tac ttc tct cca 850 Ser Thr Gly Leu Glu Asp Thr Asp Asp Ser His Leu Tyr Phe Ser Pro 215 220 225 gaa cag gga aat gtg gtg ttt acc agt gca ata gat ggg tgg ggc ttt 898 Glu Gln Gly Asn Val Val Phe Thr Ser Ala Ile Asp Gly Trp Gly Phe 230 235 240 gga att gag cac ttc gcc aga atc tac agt caa aaa att ggc atc aaa 946 Gly Ile Glu His Phe Ala Arg Ile Tyr Ser Gln Lys Ile Gly Ile Lys 245 250 255 aag gaa gtt ctt atg aaa acc ttg tgg gga gat tac tat ata aat atg 994 Lys Glu Val Leu Met Lys Thr Leu Trp Gly Asp Tyr Tyr Ile Asn Met 260 265 270 275 aag gct aaa aag atc atg aag ggt gat cag gcc aaa gga aag aaa cct 1042 Lys Ala Lys Lys Ile Met Lys Gly Asp Gln Ala Lys Gly Lys Lys Pro 280 285 290 tta ttt gta cag ttg atc ctg gaa aat ata tgg agt ttg tat gat gct 1090 Leu Phe Val Gln Leu Ile Leu Glu Asn Ile Trp Ser Leu Tyr Asp Ala 295 300 305 gtt ttg aaa aag gac aaa gac aaa att gat aaa ata gtg act tct tta 1138 Val Leu Lys Lys Asp Lys Asp Lys Ile Asp Lys Ile Val Thr Ser Leu 310 315 320 gga tta aaa att gga gcc cgg gag gca cga cat tca gac cct aaa gtt 1186 Gly Leu Lys Ile Gly Ala Arg Glu Ala Arg His Ser Asp Pro Lys Val 325 330 335 cag atc aac gcc att tgc agt cag tgg cta ccc ata tcc cat gct gtt 1234 Gln Ile Asn Ala Ile Cys Ser Gln Trp Leu Pro Ile Ser His Ala Val 340 345 350 355 ctt gct atg gtg tgt cag aaa ctt cct agt ccc ctt gat att aca gct 1282 Leu Ala Met Val Cys Gln Lys Leu Pro Ser Pro Leu Asp Ile Thr Ala 360 365 370 gag aga gtg gag aga ctg atg tgc aca gga tca caa act ttt gac tct 1330 Glu Arg Val Glu Arg Leu Met Cys Thr Gly Ser Gln Thr Phe Asp Ser 375 380 385 ttt cca cca gaa act caa gca ctg aaa gca gct ttt atg aaa tgt gga 1378 Phe Pro Pro Glu Thr Gln Ala Leu Lys Ala Ala Phe Met Lys Cys Gly 390 395 400 agt gag gac act gct cca gtt att ata ttt gtt tcc aaa atg ttt gca 1426 Ser Glu Asp Thr Ala Pro Val Ile Ile Phe Val Ser Lys Met Phe Ala 405 410 415 gtt gat gct aag gcc ttg cct cag aat aag cca agg cct ctc act caa 1474 Val Asp Ala Lys Ala Leu Pro Gln Asn Lys Pro Arg Pro Leu Thr Gln 420 425 430 435 gaa gaa att gct cag aga cgt gag cgt gca aga caa agg cat gca gag 1522 Glu Glu Ile Ala Gln Arg Arg Glu Arg Ala Arg Gln Arg His Ala Glu 440 445 450 aag ctt gca gca gca cag gga cag gca ccc ttg gag ccc acc caa gat 1570 Lys Leu Ala Ala Ala Gln Gly Gln Ala Pro Leu Glu Pro Thr Gln Asp 455 460 465 ggg agt gcc att gaa aca tgt cca aaa gga gac gag cca aga ggt gac 1618 Gly Ser Ala Ile Glu Thr Cys Pro Lys Gly Asp Glu Pro Arg Gly Asp 470 475 480 gag caa cag gtg gaa agt atg acc cct aaa cct gtg ctc cag gaa gaa 1666 Glu Gln Gln Val Glu Ser Met Thr Pro Lys Pro Val Leu Gln Glu Glu 485 490 495 aac aac caa gag tct ttt att gca ttt gct cgg gtg ttc agt ggt gtg 1714 Asn Asn Gln Glu Ser Phe Ile Ala Phe Ala Arg Val Phe Ser Gly Val 500 505 510 515 gct cga aga gga aag aaa att ttt gtc ttg ggg ccc aaa tac agt cct 1762 Ala Arg Arg Gly Lys Lys Ile Phe Val Leu Gly Pro Lys Tyr Ser Pro 520 525 530 ctt gag ttt tta cga agg gta cca tta ggc ttc tca gct cca cca gat 1810 Leu Glu Phe Leu Arg Arg Val Pro Leu Gly Phe Ser Ala Pro Pro Asp 535 540 545 ggc ctc ccc caa gtc ccc cac atg gca tac tgt gct ctg gaa aac ctg 1858 Gly Leu Pro Gln Val Pro His Met Ala Tyr Cys Ala Leu Glu Asn Leu 550 555 560 tat ctt ctg atg gga agg gaa ctg gaa tat cta gag gag gta cct cca 1906 Tyr Leu Leu Met Gly Arg Glu Leu Glu Tyr Leu Glu Glu Val Pro Pro 565 570 575 gga aat gtg cta gga ata gga ggc ctt caa gat ttt gtg ctg aaa tct 1954 Gly Asn Val Leu Gly Ile Gly Gly Leu Gln Asp Phe Val Leu Lys Ser 580 585 590 595 gca aca ctg tgt agc ctg cca tcc tgc cca cca ttt ata cca ctc aac 2002 Ala Thr Leu Cys Ser Leu Pro Ser Cys Pro Pro Phe Ile Pro Leu Asn 600 605 610 ttc gaa gcc act cct att gtg aga gtt gct gtt gaa cca aaa cat cca 2050 Phe Glu Ala Thr Pro Ile Val Arg Val Ala Val Glu Pro Lys His Pro 615 620 625 agt gaa atg cct cag ctc gta aaa gga atg aaa ctg tta aac cag gct 2098 Ser Glu Met Pro Gln Leu Val Lys Gly Met Lys Leu Leu Asn Gln Ala 630 635 640 gat ccc tgt gtc cag att tta att cag gaa acg gga gag cac gtt tta 2146 Asp Pro Cys Val Gln Ile Leu Ile Gln Glu Thr Gly Glu His Val Leu 645 650 655 gtc aca gca gga gaa gtc cac ctt cag cga tgc ctg gat gac tta aaa 2194 Val Thr Ala Gly Glu Val His Leu Gln Arg Cys Leu Asp Asp Leu Lys 660 665 670 675 gaa agg ttt gca aag att cat atc agt gta tct gaa cct att att cca 2242 Glu Arg Phe Ala Lys Ile His Ile Ser Val Ser Glu Pro Ile Ile Pro 680 685 690 ttc aga gaa aca atc aca aaa ccc cca aaa gtt gac atg gtc aat gaa 2290 Phe Arg Glu Thr Ile Thr Lys Pro Pro Lys Val Asp Met Val Asn Glu 695 700 705 gaa ata ggc aaa cag caa aaa gtt gca gtc ata cac caa atg aaa gaa 2338 Glu Ile Gly Lys Gln Gln Lys Val Ala Val Ile His Gln Met Lys Glu 710 715 720 gat caa agc aaa atc cct gaa gga atc caa gtt gac tct gac ggg cta 2386 Asp Gln Ser Lys Ile Pro Glu Gly Ile Gln Val Asp Ser Asp Gly Leu 725 730 735 atc acc ata aca act ccc aat aaa ctt gcc acg ctc agt gtt cga gcc 2434 Ile Thr Ile Thr Thr Pro Asn Lys Leu Ala Thr Leu Ser Val Arg Ala 740 745 750 755 atg ccc ctt cca gaa gaa gtc acc cag att ctg gaa gaa aat agt gat 2482 Met Pro Leu Pro Glu Glu Val Thr Gln Ile Leu Glu Glu Asn Ser Asp 760 765 770 ttg att cgt tct atg gag cag ttg aca tcc tct ttg aat gag ggt gaa 2530 Leu Ile Arg Ser Met Glu Gln Leu Thr Ser Ser Leu Asn Glu Gly Glu 775 780 785 aat act cac atg att cat cag aag acc caa gag aaa att tgg gaa ttc 2578 Asn Thr His Met Ile His Gln Lys Thr Gln Glu Lys Ile Trp Glu Phe 790 795 800 aaa gga aaa ctg gag caa cac cta aca ggg aga aga tgg agg aac att 2626 Lys Gly Lys Leu Glu Gln His Leu Thr Gly Arg Arg Trp Arg Asn Ile 805 810 815 gtt gac caa atc tgg tca ttt ggc cca aga aaa tgt ggg ccc aac ata 2674 Val Asp Gln Ile Trp Ser Phe Gly Pro Arg Lys Cys Gly Pro Asn Ile 820 825 830 835 cta gtc aat aaa agt gaa gat ttt cag aac tca gta tgg aca ggt cca 2722 Leu Val Asn Lys Ser Glu Asp Phe Gln Asn Ser Val Trp Thr Gly Pro 840 845 850 gct gac aaa gct tca aaa gaa gcc agt aga tac cga gat ttg ggc aat 2770 Ala Asp Lys Ala Ser Lys Glu Ala Ser Arg Tyr Arg Asp Leu Gly Asn 855 860 865 agc att gtg agt ggc ttc caa cta gca acc ctc tct ggc ccc atg tgt 2818 Ser Ile Val Ser Gly Phe Gln Leu Ala Thr Leu Ser Gly Pro Met Cys 870 875 880 gag gag cct ctc atg ggt gtc tgt ttt gtt ctg gaa aaa tgg gac cta 2866 Glu Glu Pro Leu Met Gly Val Cys Phe Val Leu Glu Lys Trp Asp Leu 885 890 895 agt aaa ttt gag gaa caa gga gca agt gat ctg gca aaa gag gga cag 2914 Ser Lys Phe Glu Glu Gln Gly Ala Ser Asp Leu Ala Lys Glu Gly Gln 900 905 910 915 gag gaa aat gaa acc tgt tct ggt gga aat gaa aac caa gag cta caa 2962 Glu Glu Asn Glu Thr Cys Ser Gly Gly Asn Glu Asn Gln Glu Leu Gln 920 925 930 gat ggc tgc tct gag gcc ttt gag aag agg aca tca cag aaa gga gaa 3010 Asp Gly Cys Ser Glu Ala Phe Glu Lys Arg Thr Ser Gln Lys Gly Glu 935 940 945 tct cca ctc act gac tgc tat gga cct ttc tca gga cag cta att gcc 3058 Ser Pro Leu Thr Asp Cys Tyr Gly Pro Phe Ser Gly Gln Leu Ile Ala 950 955 960 acc atg aaa gaa gca tgt cgc tat gca ctg caa gtg aaa cct cag cgc 3106 Thr Met Lys Glu Ala Cys Arg Tyr Ala Leu Gln Val Lys Pro Gln Arg 965 970 975 ctg atg gca gct atg tac aca tgt gac atc atg gcc act ggt gat gtt 3154 Leu Met Ala Ala Met Tyr Thr Cys Asp Ile Met Ala Thr Gly Asp Val 980 985 990 995 ctc ggt cga gtc tat gct gtc ttg tca aag aga gaa ggt cgg gta ctt 3202 Leu Gly Arg Val Tyr Ala Val Leu Ser Lys Arg Glu Gly Arg Val Leu 1000 1005 1010 caa gaa gaa atg aaa gaa ggg aca gac atg ttc atc atc aag gct gtg 3250 Gln Glu Glu Met Lys Glu Gly Thr Asp Met Phe Ile Ile Lys Ala Val 1015 1020 1025 ctg cct gtt gct gaa agc ttt ggt ttt gct gat gaa atc agg aag agg 3298 Leu Pro Val Ala Glu Ser Phe Gly Phe Ala Asp Glu Ile Arg Lys Arg 1030 1035 1040 aca agt ggc ctg gcc agc cca caa cta gta ttc agc cat tgg gag atc 3346 Thr Ser Gly Leu Ala Ser Pro Gln Leu Val Phe Ser His Trp Glu Ile 1045 1050 1055 att ccc agt gac ccc ttc tgg gtg cca act act gag gag gaa tac ttg 3394 Ile Pro Ser Asp Pro Phe Trp Val Pro Thr Thr Glu Glu Glu Tyr Leu 1060 1065 1070 1075 cac ttt ggg gag aag gct gac tct gag aac caa gcc cgg aag tac atg 3442 His Phe Gly Glu Lys Ala Asp Ser Glu Asn Gln Ala Arg Lys Tyr Met 1080 1085 1090 aac gca gta cga aag cgg aag ggg ctt tat gtg gaa gaa aag att gtg 3490 Asn Ala Val Arg Lys Arg Lys Gly Leu Tyr Val Glu Glu Lys Ile Val 1095 1100 1105 gag cat gca gaa aag cag agg aca ctc agc aaa aat aag tag 3532 Glu His Ala Glu Lys Gln Arg Thr Leu Ser Lys Asn Lys 1110 1115 1120 ctacctacta ctggtggatt cttttcctta tagtgaattt aaaagtatca tcaagggttt 3592 aatattggga aaatttcttt ttgccacatt atctctgttt attcactttc aataaagttg 3652 atccatataa atattttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 3709 2 1120 PRT Homo sapiens 2 Met Val Leu Asn Ser Leu Asp Lys Met Ile Gln Leu Gln Lys Asn Thr 1 5 10 15 Ala Asn Ile Arg Asn Ile Cys Val Leu Ala His Val Asp His Gly Lys 20 25 30 Thr Thr Leu Ala Asp Cys Leu Ile Ser Ser Asn Gly Ile Ile Ser Ser 35 40 45 Arg Leu Ala Gly Lys Leu Arg Tyr Met Asp Ser Arg Glu Asp Glu Gln 50 55 60 Ile Arg Gly Ile Thr Met Lys Ser Ser Ala Ile Ser Leu His Tyr Ala 65 70 75 80 Thr Gly Asn Glu Glu Tyr Leu Ile Asn Leu Ile Asp Ser Pro Gly His 85 90 95 Val Asp Phe Ser Ser Glu Val Ser Thr Ala Val Arg Ile Cys Asp Gly 100 105 110 Cys Ile Ile Val Val Asp Ala Val Glu Gly Val Cys Pro Gln Thr Gln 115 120 125 Ala Val Leu Arg Gln Ala Trp Leu Glu Asn Ile Arg Pro Val Leu Val 130 135 140 Ile Asn Lys Ile Asp Arg Leu Ile Val Glu Leu Lys Phe Thr Pro Gln 145 150 155 160 Glu Ala Tyr Ser His Leu Lys Asn Ile Leu Glu Gln Ile Asn Ala Leu 165 170 175 Thr Gly Thr Leu Phe Thr Ser Lys Val Leu Glu Glu Arg Ala Glu Arg 180 185 190 Glu Thr Glu Ser Gln Val Asn Pro Asn Ser Glu Gln Gly Glu Gln Val 195 200 205 Tyr Asp Trp Ser Thr Gly Leu Glu Asp Thr Asp Asp Ser His Leu Tyr 210 215 220 Phe Ser Pro Glu Gln Gly Asn Val Val Phe Thr Ser Ala Ile Asp Gly 225 230 235 240 Trp Gly Phe Gly Ile Glu His Phe Ala Arg Ile Tyr Ser Gln Lys Ile 245 250 255 Gly Ile Lys Lys Glu Val Leu Met Lys Thr Leu Trp Gly Asp Tyr Tyr 260 265 270 Ile Asn Met Lys Ala Lys Lys Ile Met Lys Gly Asp Gln Ala Lys Gly 275 280 285 Lys Lys Pro Leu Phe Val Gln Leu Ile Leu Glu Asn Ile Trp Ser Leu 290 295 300 Tyr Asp Ala Val Leu Lys Lys Asp Lys Asp Lys Ile Asp Lys Ile Val 305 310 315 320 Thr Ser Leu Gly Leu Lys Ile Gly Ala Arg Glu Ala Arg His Ser Asp 325 330 335 Pro Lys Val Gln Ile Asn Ala Ile Cys Ser Gln Trp Leu Pro Ile Ser 340 345 350 His Ala Val Leu Ala Met Val Cys Gln Lys Leu Pro Ser Pro Leu Asp 355 360 365 Ile Thr Ala Glu Arg Val Glu Arg Leu Met Cys Thr Gly Ser Gln Thr 370 375 380 Phe Asp Ser Phe Pro Pro Glu Thr Gln Ala Leu Lys Ala Ala Phe Met 385 390 395 400 Lys Cys Gly Ser Glu Asp Thr Ala Pro Val Ile Ile Phe Val Ser Lys 405 410 415 Met Phe Ala Val Asp Ala Lys Ala Leu Pro Gln Asn Lys Pro Arg Pro 420 425 430 Leu Thr Gln Glu Glu Ile Ala Gln Arg Arg Glu Arg Ala Arg Gln Arg 435 440 445 His Ala Glu Lys Leu Ala Ala Ala Gln Gly Gln Ala Pro Leu Glu Pro 450 455 460 Thr Gln Asp Gly Ser Ala Ile Glu Thr Cys Pro Lys Gly Asp Glu Pro 465 470 475 480 Arg Gly Asp Glu Gln Gln Val Glu Ser Met Thr Pro Lys Pro Val Leu 485 490 495 Gln Glu Glu Asn Asn Gln Glu Ser Phe Ile Ala Phe Ala Arg Val Phe 500 505 510 Ser Gly Val Ala Arg Arg Gly Lys Lys Ile Phe Val Leu Gly Pro Lys 515 520 525 Tyr Ser Pro Leu Glu Phe Leu Arg Arg Val Pro Leu Gly Phe Ser Ala 530 535 540 Pro Pro Asp Gly Leu Pro Gln Val Pro His Met Ala Tyr Cys Ala Leu 545 550 555 560 Glu Asn Leu Tyr Leu Leu Met Gly Arg Glu Leu Glu Tyr Leu Glu Glu 565 570 575 Val Pro Pro Gly Asn Val Leu Gly Ile Gly Gly Leu Gln Asp Phe Val 580 585 590 Leu Lys Ser Ala Thr Leu Cys Ser Leu Pro Ser Cys Pro Pro Phe Ile 595 600 605 Pro Leu Asn Phe Glu Ala Thr Pro Ile Val Arg Val Ala Val Glu Pro 610 615 620 Lys His Pro Ser Glu Met Pro Gln Leu Val Lys Gly Met Lys Leu Leu 625 630 635 640 Asn Gln Ala Asp Pro Cys Val Gln Ile Leu Ile Gln Glu Thr Gly Glu 645 650 655 His Val Leu Val Thr Ala Gly Glu Val His Leu Gln Arg Cys Leu Asp 660 665 670 Asp Leu Lys Glu Arg Phe Ala Lys Ile His Ile Ser Val Ser Glu Pro 675 680 685 Ile Ile Pro Phe Arg Glu Thr Ile Thr Lys Pro Pro Lys Val Asp Met 690 695 700 Val Asn Glu Glu Ile Gly Lys Gln Gln Lys Val Ala Val Ile His Gln 705 710 715 720 Met Lys Glu Asp Gln Ser Lys Ile Pro Glu Gly Ile Gln Val Asp Ser 725 730 735 Asp Gly Leu Ile Thr Ile Thr Thr Pro Asn Lys Leu Ala Thr Leu Ser 740 745 750 Val Arg Ala Met Pro Leu Pro Glu Glu Val Thr Gln Ile Leu Glu Glu 755 760 765 Asn Ser Asp Leu Ile Arg Ser Met Glu Gln Leu Thr Ser Ser Leu Asn 770 775 780 Glu Gly Glu Asn Thr His Met Ile His Gln Lys Thr Gln Glu Lys Ile 785 790 795 800 Trp Glu Phe Lys Gly Lys Leu Glu Gln His Leu Thr Gly Arg Arg Trp 805 810 815 Arg Asn Ile Val Asp Gln Ile Trp Ser Phe Gly Pro Arg Lys Cys Gly 820 825 830 Pro Asn Ile Leu Val Asn Lys Ser Glu Asp Phe Gln Asn Ser Val Trp 835 840 845 Thr Gly Pro Ala Asp Lys Ala Ser Lys Glu Ala Ser Arg Tyr Arg Asp 850 855 860 Leu Gly Asn Ser Ile Val Ser Gly Phe Gln Leu Ala Thr Leu Ser Gly 865 870 875 880 Pro Met Cys Glu Glu Pro Leu Met Gly Val Cys Phe Val Leu Glu Lys 885 890 895 Trp Asp Leu Ser Lys Phe Glu Glu Gln Gly Ala Ser Asp Leu Ala Lys 900 905 910 Glu Gly Gln Glu Glu Asn Glu Thr Cys Ser Gly Gly Asn Glu Asn Gln 915 920 925 Glu Leu Gln Asp Gly Cys Ser Glu Ala Phe Glu Lys Arg Thr Ser Gln 930 935 940 Lys Gly Glu Ser Pro Leu Thr Asp Cys Tyr Gly Pro Phe Ser Gly Gln 945 950 955 960 Leu Ile Ala Thr Met Lys Glu Ala Cys Arg Tyr Ala Leu Gln Val Lys 965 970 975 Pro Gln Arg Leu Met Ala Ala Met Tyr Thr Cys Asp Ile Met Ala Thr 980 985 990 Gly Asp Val Leu Gly Arg Val Tyr Ala Val Leu Ser Lys Arg Glu Gly 995 1000 1005 Arg Val Leu Gln Glu Glu Met Lys Glu Gly Thr Asp Met Phe Ile Ile 1010 1015 1020 Lys Ala Val Leu Pro Val Ala Glu Ser Phe Gly Phe Ala Asp Glu Ile 1025 1030 1035 1040 Arg Lys Arg Thr Ser Gly Leu Ala Ser Pro Gln Leu Val Phe Ser His 1045 1050 1055 Trp Glu Ile Ile Pro Ser Asp Pro Phe Trp Val Pro Thr Thr Glu Glu 1060 1065 1070 Glu Tyr Leu His Phe Gly Glu Lys Ala Asp Ser Glu Asn Gln Ala Arg 1075 1080 1085 Lys Tyr Met Asn Ala Val Arg Lys Arg Lys Gly Leu Tyr Val Glu Glu 1090 1095 1100 Lys Ile Val Glu His Ala Glu Lys Gln Arg Thr Leu Ser Lys Asn Lys 1105 1110 1115 1120 3 3533 DNA Homo sapiens CDS (14)..(3478) 3 ggcacgagcg gtc atg gag gcg ggc gcc gga gcc ggc gcg gga gcc gcg 49 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala 1 5 10 ggc tgg agc tgc ccg ggc cca gga ccc aca gtg acc act cta ggc tcc 97 Gly Trp Ser Cys Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser 15 20 25 tat gag gct tcc gag ggc tgt gag agg aag aag ggc caa cgc tgg ggg 145 Tyr Glu Ala Ser Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly 30 35 40 tcc ctg gaa cga cgg ggg atg caa gct atg gag ggg gag gtg tta ctc 193 Ser Leu Glu Arg Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu 45 50 55 60 cca gct ctc tat gag gag gaa gag gaa gag gaa gag gag gaa gaa gag 241 Pro Ala Leu Tyr Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 65 70 75 gtg gaa gaa gaa gaa gaa caa gtg cag aaa ggt ggc agt gtt ggc tct 289 Val Glu Glu Glu Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser 80 85 90 ctg tca gtc aac aag cac cgg gga ctg agc ctc acg gag aca gag ctg 337 Leu Ser Val Asn Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu 95 100 105 gag gag ctg cgg gct cag gtg ctg cag ctg gtg gca gaa ctg gag gag 385 Glu Glu Leu Arg Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu 110 115 120 acc cgg gaa ctg gca ggg cag cat gag gat gac tcc ttg gag cta cag 433 Thr Arg Glu Leu Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln 125 130 135 140 ggg ctc ctg gag gat gaa cgg cta gcc agc gcc cag cag gca gag gtg 481 Gly Leu Leu Glu Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val 145 150 155 ttc acc aag cag atc cag cag ctc caa ggt gag ctg cgt tct cta cgg 529 Phe Thr Lys Gln Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg 160 165 170 gag gag att tcc ctg tta gag cat gag aaa gaa agc gaa ctt aag gaa 577 Glu Glu Ile Ser Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu 175 180 185 ata gaa cag gaa ttg cat ttg gcc cag gct gag atc cag agt ctg cgg 625 Ile Glu Gln Glu Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg 190 195 200 caa gca gca gag gat tcc gca act gaa cat gag agt gac ata gca tcc 673 Gln Ala Ala Glu Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser 205 210 215 220 ctg cag gag gat ctc tgc cgg atg cag aat gaa ctt gaa gac atg gaa 721 Leu Gln Glu Asp Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu 225 230 235 cgc att cgg gga gat tat gag atg gag atc gcc tcc ctc cgt gca gaa 769 Arg Ile Arg Gly Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu 240 245 250 atg gaa atg aag agc tct gaa cca tcc ggt agt tta ggt ctc tca gat 817 Met Glu Met Lys Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp 255 260 265 tac tct ggg tta caa gaa gaa ctg cag gag ctg cgg gaa cgc tac cat 865 Tyr Ser Gly Leu Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His 270 275 280 ttc ctg aat gag gaa tac cgg gcc ctg cag gag agc aac agc agc ctc 913 Phe Leu Asn Glu Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu 285 290 295 300 acg ggg cag ctt gca gat ctg gag agt gag agg aca cag aga gca aca 961 Thr Gly Gln Leu Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr 305 310 315 gag aga tgg ctg cag tcc caa aca ctg agt atg acg tca gca gag tct 1009 Glu Arg Trp Leu Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser 320 325 330 cag act tca gaa atg gat ttc tta gag cct gat cct gaa atg cag ttg 1057 Gln Thr Ser Glu Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu 335 340 345 tta cgg cag cag cta cgg gat gct gaa gag cag atg cat ggc atg aag 1105 Leu Arg Gln Gln Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys 350 355 360 aac aag tgt cag gaa ttg tgt tgt gag ttg gaa gag cta cag cat cat 1153 Asn Lys Cys Gln Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His 365 370 375 380 cgc cag gtc agt gag gag gag cag agg cgg ctg cag agg gag ctc aag 1201 Arg Gln Val Ser Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys 385 390 395 tgt gct cag aat gag gtg ctt cgg ttt cag acc tcc cac agt gtc acc 1249 Cys Ala Gln Asn Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr 400 405 410 cag gag tta ctg tgc cgg ctg cag aag ctg cac ctc cag cac cag aac 1297 Gln Glu Leu Leu Cys Arg Leu Gln Lys Leu His Leu Gln His Gln Asn 415 420 425 gtc aca tgt gag aag gaa aag ctg ctg gaa cgg cag cag cag ctg cag 1345 Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu Gln 430 435 440 gag gag ctg cag tgc cat gag gca gag ctg cag cac ctc agg gat acg 1393 Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln His Leu Arg Asp Thr 445 450 455 460 gtg gcc tcc ttc aaa gag agc aat gag aag gac aca gag acg cac gct 1441 Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His Ala 465 470 475 cag ctt cag gag atg aag cag ctg tac cag gcc agc aag gac gag ctg 1489 Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu Leu 480 485 490 gag cgg cag aag cac atg tat gac cag ctg gag cag gac ctc ctg ctc 1537 Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu Leu 495 500 505 tgc cag ctg gag ctg aaa gag ctc aag gcc tcc cac ccc att ccg gag 1585 Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro Glu 510 515 520 gac aaa gga aag tgt gct aat aag tgt gac aca ctg ctg tcc aga ctg 1633 Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg Leu 525 530 535 540 aca gaa ttg cag gaa aag tac aag gcc agc cag aag gag atg ggg cag 1681 Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly Gln 545 550 555 ctg cag atg gag cag tgt gag ctc ctg gag gat cag agg agg atg cag 1729 Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met Gln 560 565 570 gag gag cag ggc cag ctg cag gaa gag ctg cac agg ctc aca ctg cca 1777 Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu Pro 575 580 585 ctg cca aag agt ggc ctc tta ctc aag agt cag gag cta ctc acc aag 1825 Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr Lys 590 595 600 tta gaa gac ctg tgt gag ctg cag ctg ctc tac caa ggc atg cag gag 1873 Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln Glu 605 610 615 620 gaa cag aag aag ctg ata cag aac caa gac tgt gta tta aaa gaa caa 1921 Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu Gln 625 630 635 tta gag atc cac gaa gag ctg cga cgt ttc aaa gag tct cat ttc cag 1969 Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe Gln 640 645 650 gaa gtg ttg gag aat ccc gat gat tcc aaa ttg gct aag tcc tcc aaa 2017 Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser Lys 655 660 665 tgt aat cga aac aag caa tcc aag ctg ctc atg gag cag atg cag gcc 2065 Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln Ala 670 675 680 ctg cag gtg atg tat gac gcc ggt cag gcg aag cag gag ctc ttg cag 2113 Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu Gln 685 690 695 700 caa gag caa ggg agg ctc cta gag gag cgg aag agg ctg cag gca gac 2161 Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala Asp 705 710 715 ttg cag ctc tgc ctg gaa gaa atg cag ctg ctt caa gtc cag tcc cct 2209 Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser Pro 720 725 730 tct ata aaa atg agc ctt gag tcc tac ggg aag agc tat ggt agc atg 2257 Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser Met 735 740 745 gtc ccc agc aat gag aac tgt cgc aag act tat gat acc act gtg gat 2305 Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val Asp 750 755 760 gac aat gag agc tat tac aag agt tac acc agc acc cag acc agc agc 2353 Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser Ser 765 770 775 780 aag agc ttt ctc aag agc tat gac agc agc acc agt gcc agt gag gcc 2401 Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu Ala 785 790 795 tat ggg aag agt tac tgc act acc agc aac agc agc att acc tat aag 2449 Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr Lys 800 805 810 aag agt tac ggc agc acc agt agc tct gac acc tgc cag aag agt ttt 2497 Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser Phe 815 820 825 gtc agc agc tgc act gac gag gaa cct gct gag cct gaa gac atg gag 2545 Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met Glu 830 835 840 cgc ttt gag gaa atg gtt gtg aaa gtg ctg atc aag ctg cag gcg gtg 2593 Arg Phe Glu Glu Met Val Val Lys Val Leu Ile Lys Leu Gln Ala Val 845 850 855 860 cag gcc atg tac cag ata agc cag gag gaa cac agc cag ctg caa gag 2641 Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln Glu 865 870 875 cag atg gaa aag tta ctg gcc aag cag aaa gac ctg aag gaa gag ctg 2689 Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu Leu 880 885 890 gat gcc tgt gaa agg gag ttc aag gag tgc atg gaa tgc ctt gaa aag 2737 Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu Lys 895 900 905 ccc atg gcc ccc cag aac gac aag aat gag atc aaa gaa ctg cag acc 2785 Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln Thr 910 915 920 aag ctg cgg gag ctg cag ctg caa tac cag gct agc atg gat gag cag 2833 Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu Gln 925 930 935 940 ggg cag ctt ctg gta gtg cag gag cag ctg gag ggg cag ctg cag tgc 2881 Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln Cys 945 950 955 tgc cag gag gag ctc cgc cag ctc agg gag aag agg cct tct gtt gtc 2929 Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val Val 960 965 970 aaa gaa gcc cgg ggg aag aat gct aat aag aac atg aac aag aat gcc 2977 Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn Ala 975 980 985 aat ggg gtt aaa atg aaa aag gtg acc aag cca tgc tcg gat act tct 3025 Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr Ser 990 995 1000 gag agc gac ctt gag acc aga aag aag atc agg agg aaa atg aag agg 3073 Glu Ser Asp Leu Glu Thr Arg Lys Lys Ile Arg Arg Lys Met Lys Arg 1005 1010 1015 1020 aca aag agg aag agg aga agg aag aag aca gtg aag agg agg aag atg 3121 Thr Lys Arg Lys Arg Arg Arg Lys Lys Thr Val Lys Arg Arg Lys Met 1025 1030 1035 acg ccg act ctt ccc ttg aaa gtc ccg aag aaa ata acc ccc tca gac 3169 Thr Pro Thr Leu Pro Leu Lys Val Pro Lys Lys Ile Thr Pro Ser Asp 1040 1045 1050 ttt ccg aga gca aaa aga aca tgt ttg ggt tgt gga agc cta tgg tat 3217 Phe Pro Arg Ala Lys Arg Thr Cys Leu Gly Cys Gly Ser Leu Trp Tyr 1055 1060 1065 tct tgg cta ttg cag ctg tgg ctc tgt atg tgt tac cca aca tgc gac 3265 Ser Trp Leu Leu Gln Leu Trp Leu Cys Met Cys Tyr Pro Thr Cys Asp 1070 1075 1080 agc agg agt cag agt tct gcc tca tgg agt gat ggc aga cct tgg cca 3313 Ser Arg Ser Gln Ser Ser Ala Ser Trp Ser Asp Gly Arg Pro Trp Pro 1085 1090 1095 1100 gcg cga ggg cag atc ccc agt ggc cac cac cct cag ctt tgg gca gga 3361 Ala Arg Gly Gln Ile Pro Ser Gly His His Pro Gln Leu Trp Ala Gly 1105 1110 1115 cac act gtg cca gaa ccc tcc cca tat gtt cca tgt gtc ccc atc tcc 3409 His Thr Val Pro Glu Pro Ser Pro Tyr Val Pro Cys Val Pro Ile Ser 1120 1125 1130 tca gcc tca gtc acc cag gct gaa aag gct tgt ggg gag cgg ctg act 3457 Ser Ala Ser Val Thr Gln Ala Glu Lys Ala Cys Gly Glu Arg Leu Thr 1135 1140 1145 tcc atc tcc tgc ctt gtg taa gaacctgagt tccttgtaat taaatatcaa 3508 Ser Ile Ser Cys Leu Val 1150 1155 ctgaattaaa aaaaaaaaaa aaaaa 3533 4 1154 PRT Homo sapiens 4 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala Gly Trp Ser Cys 1 5 10 15 Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser Tyr Glu Ala Ser 20 25 30 Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly Ser Leu Glu Arg 35 40 45 Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu Pro Ala Leu Tyr 50 55 60 Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Glu 65 70 75 80 Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser Leu Ser Val Asn 85 90 95 Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu Glu Glu Leu Arg 100 105 110 Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu Thr Arg Glu Leu 115 120 125 Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln Gly Leu Leu Glu 130 135 140 Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val Phe Thr Lys Gln 145 150 155 160 Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg Glu Glu Ile Ser 165 170 175 Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu Ile Glu Gln Glu 180 185 190 Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg Gln Ala Ala Glu 195 200 205 Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser Leu Gln Glu Asp 210 215 220 Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu Arg Ile Arg Gly 225 230 235 240 Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu Met Glu Met Lys 245 250 255 Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp Tyr Ser Gly Leu 260 265 270 Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His Phe Leu Asn Glu 275 280 285 Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu Thr Gly Gln Leu 290 295 300 Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr Glu Arg Trp Leu 305 310 315 320 Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser Gln Thr Ser Glu 325 330 335 Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu Leu Arg Gln Gln 340 345 350 Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys Asn Lys Cys Gln 355 360 365 Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His Arg Gln Val Ser 370 375 380 Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys Cys Ala Gln Asn 385 390 395 400 Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr Gln Glu Leu Leu 405 410 415 Cys Arg Leu Gln Lys Leu His Leu Gln His Gln Asn Val Thr Cys Glu 420 425 430 Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu Gln Glu Glu Leu Gln 435 440 445 Cys His Glu Ala Glu Leu Gln His Leu Arg Asp Thr Val Ala Ser Phe 450 455 460 Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His Ala Gln Leu Gln Glu 465 470 475 480 Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu Leu Glu Arg Gln Lys 485 490 495 His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu Leu Cys Gln Leu Glu 500 505 510 Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro Glu Asp Lys Gly Lys 515 520 525 Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg Leu Thr Glu Leu Gln 530 535 540 Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly Gln Leu Gln Met Glu 545 550 555 560 Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met Gln Glu Glu Gln Gly 565 570 575 Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu Pro Leu Pro Lys Ser 580 585 590 Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr Lys Leu Glu Asp Leu 595 600 605 Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln Glu Glu Gln Lys Lys 610 615 620 Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu Gln Leu Glu Ile His 625 630 635 640 Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe Gln Glu Val Leu Glu 645 650 655 Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser Lys Cys Asn Arg Asn 660 665 670 Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln Ala Leu Gln Val Met 675 680 685 Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu Gln Gln Glu Gln Gly 690 695 700 Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala Asp Leu Gln Leu Cys 705 710 715 720 Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser Pro Ser Ile Lys Met 725 730 735 Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser Met Val Pro Ser Asn 740 745 750 Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val Asp Asp Asn Glu Ser 755 760 765 Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser Ser Lys Ser Phe Leu 770 775 780 Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu Ala Tyr Gly Lys Ser 785 790 795 800 Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr Lys Lys Ser Tyr Gly 805 810 815 Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser Phe Val Ser Ser Cys 820 825 830 Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met Glu Arg Phe Glu Glu 835 840 845 Met Val Val Lys Val Leu Ile Lys Leu Gln Ala Val Gln Ala Met Tyr 850 855 860 Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln Glu Gln Met Glu Lys 865 870 875 880 Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu Leu Asp Ala Cys Glu 885 890 895 Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu Lys Pro Met Ala Pro 900 905 910 Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln Thr Lys Leu Arg Glu 915 920 925 Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu Gln Gly Gln Leu Leu 930 935 940 Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln Cys Cys Gln Glu Glu 945 950 955 960 Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val Val Lys Glu Ala Arg 965 970 975 Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn Ala Asn Gly Val Lys 980 985 990 Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr Ser Glu Ser Asp Leu 995 1000 1005 Glu Thr Arg Lys Lys Ile Arg Arg Lys Met Lys Arg Thr Lys Arg Lys 1010 1015 1020 Arg Arg Arg Lys Lys Thr Val Lys Arg Arg Lys Met Thr Pro Thr Leu 1025 1030 1035 1040 Pro Leu Lys Val Pro Lys Lys Ile Thr Pro Ser Asp Phe Pro Arg Ala 1045 1050 1055 Lys Arg Thr Cys Leu Gly Cys Gly Ser Leu Trp Tyr Ser Trp Leu Leu 1060 1065 1070 Gln Leu Trp Leu Cys Met Cys Tyr Pro Thr Cys Asp Ser Arg Ser Gln 1075 1080 1085 Ser Ser Ala Ser Trp Ser Asp Gly Arg Pro Trp Pro Ala Arg Gly Gln 1090 1095 1100 Ile Pro Ser Gly His His Pro Gln Leu Trp Ala Gly His Thr Val Pro 1105 1110 1115 1120 Glu Pro Ser Pro Tyr Val Pro Cys Val Pro Ile Ser Ser Ala Ser Val 1125 1130 1135 Thr Gln Ala Glu Lys Ala Cys Gly Glu Arg Leu Thr Ser Ile Ser Cys 1140 1145 1150 Leu Val 5 3714 DNA Homo sapiens CDS (14)..(3478) 5 ggcacgagcg gtc atg gag gcg ggc gcc gga gcc ggc gcg gga gcc gcg 49 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala 1 5 10 ggc tgg agc tgc ccg ggc cca gga ccc aca gtg acc act cta ggc tcc 97 Gly Trp Ser Cys Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser 15 20 25 tat gag gct tcc gag ggc tgt gag agg aag aag ggc caa cgc tgg ggg 145 Tyr Glu Ala Ser Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly 30 35 40 tcc ctg gaa cga cgg ggg atg caa gct atg gag ggg gag gtg tta ctc 193 Ser Leu Glu Arg Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu 45 50 55 60 cca gct ctc tat gag gag gaa gag gaa gag gaa gag gag gaa gaa gag 241 Pro Ala Leu Tyr Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 65 70 75 gtg gaa gaa gaa gaa gaa caa gtg cag aaa ggt ggc agt gtt ggc tct 289 Val Glu Glu Glu Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser 80 85 90 ctg tca gtc aac aag cac cgg gga ctg agc ctc acg gag aca gag ctg 337 Leu Ser Val Asn Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu 95 100 105 gag gag ctg cgg gct cag gtg ctg cag ctg gtg gca gaa ctg gag gag 385 Glu Glu Leu Arg Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu 110 115 120 acc cgg gaa ctg gca ggg cag cat gag gat gac tcc ttg gag cta cag 433 Thr Arg Glu Leu Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln 125 130 135 140 ggg ctc ctg gag gat gaa cgg cta gcc agc gcc cag cag gca gag gtg 481 Gly Leu Leu Glu Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val 145 150 155 ttc acc aag cag atc cag cag ctc caa ggt gag ctg cgt tct cta cgg 529 Phe Thr Lys Gln Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg 160 165 170 gag gag att tcc ctg tta gag cat gag aaa gaa agc gaa ctt aag gaa 577 Glu Glu Ile Ser Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu 175 180 185 ata gaa cag gaa ttg cat ttg gcc cag gct gag atc cag agt ctg cgg 625 Ile Glu Gln Glu Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg 190 195 200 caa gca gca gag gat tcc gca act gaa cat gag agt gac ata gca tcc 673 Gln Ala Ala Glu Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser 205 210 215 220 ctg cag gag gat ctc tgc cgg atg cag aat gaa ctt gaa gac atg gaa 721 Leu Gln Glu Asp Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu 225 230 235 cgc att cgg gga gat tat gag atg gag atc gcc tcc ctc cgt gca gaa 769 Arg Ile Arg Gly Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu 240 245 250 atg gaa atg aag agc tct gaa cca tcc ggt agt tta ggt ctc tca gat 817 Met Glu Met Lys Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp 255 260 265 tac tct ggg tta caa gaa gaa ctg cag gag ctg cgg gaa cgc tac cat 865 Tyr Ser Gly Leu Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His 270 275 280 ttc ctg aat gag gaa tac cgg gcc ctg cag gag agc aac agc agc ctc 913 Phe Leu Asn Glu Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu 285 290 295 300 acg ggg cag ctt gca gat ctg gag agt gag agg aca cag aga gca aca 961 Thr Gly Gln Leu Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr 305 310 315 gag aga tgg ctg cag tcc caa aca ctg agt atg acg tca gca gag tct 1009 Glu Arg Trp Leu Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser 320 325 330 cag act tca gaa atg gat ttc tta gag cct gat cct gaa atg cag ttg 1057 Gln Thr Ser Glu Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu 335 340 345 tta cgg cag cag cta cgg gat gct gaa gag cag atg cat ggc atg aag 1105 Leu Arg Gln Gln Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys 350 355 360 aac aag tgt cag gaa ttg tgt tgt gag ttg gaa gag cta cag cat cat 1153 Asn Lys Cys Gln Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His 365 370 375 380 cgc cag gtc agt gag gag gag cag agg cgg ctg cag agg gag ctc aag 1201 Arg Gln Val Ser Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys 385 390 395 tgt gct cag aat gag gtg ctt cgg ttt cag acc tcc cac agt gtc acc 1249 Cys Ala Gln Asn Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr 400 405 410 cag gag tta ctg tgc cgg ctg cag aag ctg cac ctc cag cac cag aac 1297 Gln Glu Leu Leu Cys Arg Leu Gln Lys Leu His Leu Gln His Gln Asn 415 420 425 gtc aca tgt gag aag gaa aag ctg ctg gaa cgg cag cag cag ctg cag 1345 Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu Gln 430 435 440 gag gag ctg cag tgc cat gag gca gag ctg cag cac ctc agg gat acg 1393 Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln His Leu Arg Asp Thr 445 450 455 460 gtg gcc tcc ttc aaa gag agc aat gag aag gac aca gag acg cac gct 1441 Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His Ala 465 470 475 cag ctt cag gag atg aag cag ctg tac cag gcc agc aag gac gag ctg 1489 Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu Leu 480 485 490 gag cgg cag aag cac atg tat gac cag ctg gag cag gac ctc ctg ctc 1537 Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu Leu 495 500 505 tgc cag ctg gag ctg aaa gag ctc aag gcc tcc cac ccc att ccg gag 1585 Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro Glu 510 515 520 gac aaa gga aag tgt gct aat aag tgt gac aca ctg ctg tcc aga ctg 1633 Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg Leu 525 530 535 540 aca gaa ttg cag gaa aag tac aag gcc agc cag aag gag atg ggg cag 1681 Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly Gln 545 550 555 ctg cag atg gag cag tgt gag ctc ctg gag gat cag agg agg atg cag 1729 Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met Gln 560 565 570 gag gag cag ggc cag ctg cag gaa gag ctg cac agg ctc aca ctg cca 1777 Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu Pro 575 580 585 ctg cca aag agt ggc ctc tta ctc aag agt cag gag cta ctc acc aag 1825 Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr Lys 590 595 600 tta gaa gac ctg tgt gag ctg cag ctg ctc tac caa ggc atg cag gag 1873 Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln Glu 605 610 615 620 gaa cag aag aag ctg ata cag aac caa gac tgt gta tta aaa gaa caa 1921 Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu Gln 625 630 635 tta gag atc cac gaa gag ctg cga cgt ttc aaa gag tct cat ttc cag 1969 Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe Gln 640 645 650 gaa gtg ttg gag aat ccc gat gat tcc aaa ttg gct aag tcc tcc aaa 2017 Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser Lys 655 660 665 tgt aat cga aac aag caa tcc aag ctg ctc atg gag cag atg cag gcc 2065 Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln Ala 670 675 680 ctg cag gtg atg tat gac gcc ggt cag gcg aag cag gag ctc ttg cag 2113 Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu Gln 685 690 695 700 caa gag caa ggg agg ctc cta gag gag cgg aag agg ctg cag gca gac 2161 Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala Asp 705 710 715 ttg cag ctc tgc ctg gaa gaa atg cag ctg ctt caa gtc cag tcc cct 2209 Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser Pro 720 725 730 tct ata aaa atg agc ctt gag tcc tac ggg aag agc tat ggt agc atg 2257 Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser Met 735 740 745 gtc ccc agc aat gag aac tgt cgc aag act tat gat acc act gtg gat 2305 Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val Asp 750 755 760 gac aat gag agc tat tac aag agt tac acc agc acc cag acc agc agc 2353 Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser Ser 765 770 775 780 aag agc ttt ctc aag agc tat gac agc agc acc agt gcc agt gag gcc 2401 Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu Ala 785 790 795 tat ggg aag agt tac tgc act acc agc aac agc agc att acc tat aag 2449 Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr Lys 800 805 810 aag agt tac ggc agc acc agt agc tct gac acc tgc cag aag agt ttt 2497 Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser Phe 815 820 825 gtc agc agc tgc act gac gag gaa cct gct gag cct gaa gac atg gag 2545 Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met Glu 830 835 840 cgc ttt gag gaa atg gtt gtg aaa gtg ctg atc aag ctg cag gcg gtg 2593 Arg Phe Glu Glu Met Val Val Lys Val Leu Ile Lys Leu Gln Ala Val 845 850 855 860 cag gcc atg tac cag ata agc cag gag gaa cac agc cag ctg caa gag 2641 Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln Glu 865 870 875 cag atg gaa aag tta ctg gcc aag cag aaa gac ctg aag gaa gag ctg 2689 Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu Leu 880 885 890 gat gcc tgt gaa agg gag ttc aag gag tgc atg gaa tgc ctt gaa aag 2737 Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu Lys 895 900 905 ccc atg gcc ccc cag aac gac aag aat gag atc aaa gaa ctg cag acc 2785 Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln Thr 910 915 920 aag ctg cgg gag ctg cag ctg caa tac cag gct agc atg gat gag cag 2833 Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu Gln 925 930 935 940 ggg cag ctt ctg gta gtg cag gag cag ctg gag ggg cag ctg cag tgc 2881 Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln Cys 945 950 955 tgc cag gag gag ctc cgc cag ctc agg gag aag agg cct tct gtt gtc 2929 Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val Val 960 965 970 aaa gaa gcc cgg ggg aag aat gct aat aag aac atg aac aag aat gcc 2977 Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn Ala 975 980 985 aat ggg gtt aaa atg aaa aag gtg acc aag cca tgc tcg gat act tct 3025 Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr Ser 990 995 1000 gag agc gac ctt gag acc aga aag agt ctg gag gta gtg ctg tac tac 3073 Glu Ser Asp Leu Glu Thr Arg Lys Ser Leu Glu Val Val Leu Tyr Tyr 1005 1010 1015 1020 aag gcc agc cag agg aaa tta gat gga cta gca aaa gag gag gaa aag 3121 Lys Ala Ser Gln Arg Lys Leu Asp Gly Leu Ala Lys Glu Glu Glu Lys 1025 1030 1035 aaa gag gag atg gag gag gaa aaa aag gaa gtg aaa gag gaa gca aag 3169 Lys Glu Glu Met Glu Glu Glu Lys Lys Glu Val Lys Glu Glu Ala Lys 1040 1045 1050 gag cag tgt ggg gat gag cta gtt gct gag cca gca gat cct gag gaa 3217 Glu Gln Cys Gly Asp Glu Leu Val Ala Glu Pro Ala Asp Pro Glu Glu 1055 1060 1065 gct aaa tcc aca gaa gat cag gag gaa aat gaa gag gac aaa gag gaa 3265 Ala Lys Ser Thr Glu Asp Gln Glu Glu Asn Glu Glu Asp Lys Glu Glu 1070 1075 1080 gag gag aag gaa gaa gac agt gaa gag gag gaa gat gac gcc gac tct 3313 Glu Glu Lys Glu Glu Asp Ser Glu Glu Glu Glu Asp Asp Ala Asp Ser 1085 1090 1095 1100 tcc ctt gaa agt ccc gaa gaa aat aac ccc ctc aga ctt tcc gag agc 3361 Ser Leu Glu Ser Pro Glu Glu Asn Asn Pro Leu Arg Leu Ser Glu Ser 1105 1110 1115 aaa aag aac atg ttt ggg ttg tgg aag cct atg gta ttc ttg gct att 3409 Lys Lys Asn Met Phe Gly Leu Trp Lys Pro Met Val Phe Leu Ala Ile 1120 1125 1130 gca gct gtg gct ctg tat gtg tta ccc aac atg cga cag cag gag tca 3457 Ala Ala Val Ala Leu Tyr Val Leu Pro Asn Met Arg Gln Gln Glu Ser 1135 1140 1145 gag ttc tgc ctc atg gag tga tggcagacct tggccagcgc gagggcagat 3508 Glu Phe Cys Leu Met Glu 1150 1155 ccccagtggc caccaccctc agctttgggc aggacacact gtgccagaac cctccccata 3568 tgttccatgt gtccccatct cctcagcctc agtcacccag gctgaaaagg cttgtgggga 3628 gcggctgact tccatctcct gccttgtgta agaacctgag ttccttgtaa ttaaatatca 3688 actgaattaa aaaaaaaaaa aaaaaa 3714 6 1154 PRT Homo sapiens 6 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala Gly Trp Ser Cys 1 5 10 15 Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser Tyr Glu Ala Ser 20 25 30 Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly Ser Leu Glu Arg 35 40 45 Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu Pro Ala Leu Tyr 50 55 60 Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Glu 65 70 75 80 Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser Leu Ser Val Asn 85 90 95 Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu Glu Glu Leu Arg 100 105 110 Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu Thr Arg Glu Leu 115 120 125 Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln Gly Leu Leu Glu 130 135 140 Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val Phe Thr Lys Gln 145 150 155 160 Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg Glu Glu Ile Ser 165 170 175 Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu Ile Glu Gln Glu 180 185 190 Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg Gln Ala Ala Glu 195 200 205 Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser Leu Gln Glu Asp 210 215 220 Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu Arg Ile Arg Gly 225 230 235 240 Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu Met Glu Met Lys 245 250 255 Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp Tyr Ser Gly Leu 260 265 270 Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His Phe Leu Asn Glu 275 280 285 Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu Thr Gly Gln Leu 290 295 300 Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr Glu Arg Trp Leu 305 310 315 320 Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser Gln Thr Ser Glu 325 330 335 Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu Leu Arg Gln Gln 340 345 350 Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys Asn Lys Cys Gln 355 360 365 Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His Arg Gln Val Ser 370 375 380 Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys Cys Ala Gln Asn 385 390 395 400 Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr Gln Glu Leu Leu 405 410 415 Cys Arg Leu Gln Lys Leu His Leu Gln His Gln Asn Val Thr Cys Glu 420 425 430 Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu Gln Glu Glu Leu Gln 435 440 445 Cys His Glu Ala Glu Leu Gln His Leu Arg Asp Thr Val Ala Ser Phe 450 455 460 Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His Ala Gln Leu Gln Glu 465 470 475 480 Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu Leu Glu Arg Gln Lys 485 490 495 His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu Leu Cys Gln Leu Glu 500 505 510 Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro Glu Asp Lys Gly Lys 515 520 525 Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg Leu Thr Glu Leu Gln 530 535 540 Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly Gln Leu Gln Met Glu 545 550 555 560 Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met Gln Glu Glu Gln Gly 565 570 575 Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu Pro Leu Pro Lys Ser 580 585 590 Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr Lys Leu Glu Asp Leu 595 600 605 Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln Glu Glu Gln Lys Lys 610 615 620 Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu Gln Leu Glu Ile His 625 630 635 640 Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe Gln Glu Val Leu Glu 645 650 655 Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser Lys Cys Asn Arg Asn 660 665 670 Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln Ala Leu Gln Val Met 675 680 685 Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu Gln Gln Glu Gln Gly 690 695 700 Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala Asp Leu Gln Leu Cys 705 710 715 720 Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser Pro Ser Ile Lys Met 725 730 735 Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser Met Val Pro Ser Asn 740 745 750 Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val Asp Asp Asn Glu Ser 755 760 765 Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser Ser Lys Ser Phe Leu 770 775 780 Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu Ala Tyr Gly Lys Ser 785 790 795 800 Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr Lys Lys Ser Tyr Gly 805 810 815 Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser Phe Val Ser Ser Cys 820 825 830 Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met Glu Arg Phe Glu Glu 835 840 845 Met Val Val Lys Val Leu Ile Lys Leu Gln Ala Val Gln Ala Met Tyr 850 855 860 Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln Glu Gln Met Glu Lys 865 870 875 880 Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu Leu Asp Ala Cys Glu 885 890 895 Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu Lys Pro Met Ala Pro 900 905 910 Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln Thr Lys Leu Arg Glu 915 920 925 Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu Gln Gly Gln Leu Leu 930 935 940 Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln Cys Cys Gln Glu Glu 945 950 955 960 Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val Val Lys Glu Ala Arg 965 970 975 Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn Ala Asn Gly Val Lys 980 985 990 Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr Ser Glu Ser Asp Leu 995 1000 1005 Glu Thr Arg Lys Ser Leu Glu Val Val Leu Tyr Tyr Lys Ala Ser Gln 1010 1015 1020 Arg Lys Leu Asp Gly Leu Ala Lys Glu Glu Glu Lys Lys Glu Glu Met 1025 1030 1035 1040 Glu Glu Glu Lys Lys Glu Val Lys Glu Glu Ala Lys Glu Gln Cys Gly 1045 1050 1055 Asp Glu Leu Val Ala Glu Pro Ala Asp Pro Glu Glu Ala Lys Ser Thr 1060 1065 1070 Glu Asp Gln Glu Glu Asn Glu Glu Asp Lys Glu Glu Glu Glu Lys Glu 1075 1080 1085 Glu Asp Ser Glu Glu Glu Glu Asp Asp Ala Asp Ser Ser Leu Glu Ser 1090 1095 1100 Pro Glu Glu Asn Asn Pro Leu Arg Leu Ser Glu Ser Lys Lys Asn Met 1105 1110 1115 1120 Phe Gly Leu Trp Lys Pro Met Val Phe Leu Ala Ile Ala Ala Val Ala 1125 1130 1135 Leu Tyr Val Leu Pro Asn Met Arg Gln Gln Glu Ser Glu Phe Cys Leu 1140 1145 1150 Met Glu 7 3692 DNA Homo sapiens CDS (14)..(3637) 7 ggcacgagcg gtc atg gag gcg ggc gcc gga gcc ggc gcg gga gcc gcg 49 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala 1 5 10 ggc tgg agc tgc ccg ggc cca gga ccc aca gtg acc act cta ggc tcc 97 Gly Trp Ser Cys Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser 15 20 25 tat gag gct tcc gag ggc tgt gag agg aag aag ggc caa cgc tgg ggg 145 Tyr Glu Ala Ser Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly 30 35 40 tcc ctg gaa cga cgg ggg atg caa gct atg gag ggg gag gtg tta ctc 193 Ser Leu Glu Arg Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu 45 50 55 60 cca gct ctc tat gag gag gaa gag gaa gag gaa gag gag gaa gaa gag 241 Pro Ala Leu Tyr Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 65 70 75 gtg gaa gaa gaa gaa gaa caa gtg cag aaa ggt ggc agt gtt ggc tct 289 Val Glu Glu Glu Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser 80 85 90 ctg tca gtc aac aag cac cgg gga ctg agc ctc acg gag aca gag ctg 337 Leu Ser Val Asn Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu 95 100 105 gag gag ctg cgg gct cag gtg ctg cag ctg gtg gca gaa ctg gag gag 385 Glu Glu Leu Arg Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu 110 115 120 acc cgg gaa ctg gca ggg cag cat gag gat gac tcc ttg gag cta cag 433 Thr Arg Glu Leu Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln 125 130 135 140 ggg ctc ctg gag gat gaa cgg cta gcc agc gcc cag cag gca gag gtg 481 Gly Leu Leu Glu Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val 145 150 155 ttc acc aag cag atc cag cag ctc caa ggt gag ctg cgt tct cta cgg 529 Phe Thr Lys Gln Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg 160 165 170 gag gag att tcc ctg tta gag cat gag aaa gaa agc gaa ctt aag gaa 577 Glu Glu Ile Ser Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu 175 180 185 ata gaa cag gaa ttg cat ttg gcc cag gct gag atc cag agt ctg cgg 625 Ile Glu Gln Glu Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg 190 195 200 caa gca gca gag gat tcc gca act gaa cat gag agt gac ata gca tcc 673 Gln Ala Ala Glu Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser 205 210 215 220 ctg cag gag gat ctc tgc cgg atg cag aat gaa ctt gaa gac atg gaa 721 Leu Gln Glu Asp Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu 225 230 235 cgc att cgg gga gat tat gag atg gag atc gcc tcc ctc cgt gca gaa 769 Arg Ile Arg Gly Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu 240 245 250 atg gaa atg aag agc tct gaa cca tcc ggt agt tta ggt ctc tca gat 817 Met Glu Met Lys Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp 255 260 265 tac tct ggg tta caa gaa gaa ctg cag gag ctg cgg gaa cgc tac cat 865 Tyr Ser Gly Leu Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His 270 275 280 ttc ctg aat gag gaa tac cgg gcc ctg cag gag agc aac agc agc ctc 913 Phe Leu Asn Glu Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu 285 290 295 300 acg ggg cag ctt gca gat ctg gag agt gag agg aca cag aga gca aca 961 Thr Gly Gln Leu Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr 305 310 315 gag aga tgg ctg cag tcc caa aca ctg agt atg acg tca gca gag tct 1009 Glu Arg Trp Leu Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser 320 325 330 cag act tca gaa atg gat ttc tta gag cct gat cct gaa atg cag ttg 1057 Gln Thr Ser Glu Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu 335 340 345 tta cgg cag cag cta cgg gat gct gaa gag cag atg cat ggc atg aag 1105 Leu Arg Gln Gln Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys 350 355 360 aac aag tgt cag gaa ttg tgt tgt gag ttg gaa gag cta cag cat cat 1153 Asn Lys Cys Gln Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His 365 370 375 380 cgc cag gtc agt gag gag gag cag agg cgg ctg cag agg gag ctc aag 1201 Arg Gln Val Ser Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys 385 390 395 tgt gct cag aat gag gtg ctt cgg ttt cag acc tcc cac agt gtc acc 1249 Cys Ala Gln Asn Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr 400 405 410 cag aat gag gag ctg aag tcc aga ctc tgt acc ctg cag aaa aaa tat 1297 Gln Asn Glu Glu Leu Lys Ser Arg Leu Cys Thr Leu Gln Lys Lys Tyr 415 420 425 gat act agc cag gat gag cag aac gag ctc ttg aag atg cag ctg caa 1345 Asp Thr Ser Gln Asp Glu Gln Asn Glu Leu Leu Lys Met Gln Leu Gln 430 435 440 ctt cag act gag ctc cgg cag ctc aaa gtc atg aaa tcc aca ctt gta 1393 Leu Gln Thr Glu Leu Arg Gln Leu Lys Val Met Lys Ser Thr Leu Val 445 450 455 460 gaa aac cag agt gag aag gag tta ctg tgc cgg ctg cag aag ctg cac 1441 Glu Asn Gln Ser Glu Lys Glu Leu Leu Cys Arg Leu Gln Lys Leu His 465 470 475 ctc cag cac cag aac gtc aca tgt gag aag gaa aag ctg ctg gaa cgg 1489 Leu Gln His Gln Asn Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg 480 485 490 cag cag cag ctg cag gag gag ctg cag tgc cat gag gca gag ctg cag 1537 Gln Gln Gln Leu Gln Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln 495 500 505 cac ctc agg gat acg gtg gcc tcc ttc aaa gag agc aat gag aag gac 1585 His Leu Arg Asp Thr Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp 510 515 520 aca gag acg cac gct cag ctt cag gag atg aag cag ctg tac cag gcc 1633 Thr Glu Thr His Ala Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala 525 530 535 540 agc aag gac gag ctg gag cgg cag aag cac atg tat gac cag ctg gag 1681 Ser Lys Asp Glu Leu Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu 545 550 555 cag gac ctc ctg ctc tgc cag ctg gag ctg aaa gag ctc aag gcc tcc 1729 Gln Asp Leu Leu Leu Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser 560 565 570 cac ccc att ccg gag gac aaa gga aag tgt gct aat aag tgt gac aca 1777 His Pro Ile Pro Glu Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr 575 580 585 ctg ctg tcc aga ctg aca gaa ttg cag gaa aag tac aag gcc agc cag 1825 Leu Leu Ser Arg Leu Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln 590 595 600 aag gag atg ggg cag ctg cag atg gag cag tgt gag ctc ctg gag gat 1873 Lys Glu Met Gly Gln Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp 605 610 615 620 cag agg agg atg cag gag gag cag ggc cag ctg cag gaa gag ctg cac 1921 Gln Arg Arg Met Gln Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His 625 630 635 agg ctc aca ctg cca ctg cca aag agt ggc ctc tta ctc aag agt cag 1969 Arg Leu Thr Leu Pro Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln 640 645 650 gag cta ctc acc aag tta gaa gac ctg tgt gag ctg cag ctg ctc tac 2017 Glu Leu Leu Thr Lys Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr 655 660 665 caa ggc atg cag gag gaa cag aag aag ctg ata cag aac caa gac tgt 2065 Gln Gly Met Gln Glu Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys 670 675 680 gta tta aaa gaa caa tta gag atc cac gaa gag ctg cga cgt ttc aaa 2113 Val Leu Lys Glu Gln Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys 685 690 695 700 gag tct cat ttc cag gaa gtg ttg gag aat ccc gat gat tcc aaa ttg 2161 Glu Ser His Phe Gln Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu 705 710 715 gct aag tcc tcc aaa tgt aat cga aac aag caa tcc aag ctg ctc atg 2209 Ala Lys Ser Ser Lys Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met 720 725 730 gag cag atg cag gcc ctg cag gtg atg tat gac gcc ggt cag gcg aag 2257 Glu Gln Met Gln Ala Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys 735 740 745 cag gag ctc ttg cag caa gag caa ggg agg ctc cta gag gag cgg aag 2305 Gln Glu Leu Leu Gln Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys 750 755 760 agg ctg cag gca gac ttg cag ctc tgc ctg gaa gaa atg cag ctg ctt 2353 Arg Leu Gln Ala Asp Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu 765 770 775 780 caa gtc cag tcc cct tct ata aaa atg agc ctt gag tcc tac ggg aag 2401 Gln Val Gln Ser Pro Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys 785 790 795 agc tat ggt agc atg gtc ccc agc aat gag aac tgt cgc aag act tat 2449 Ser Tyr Gly Ser Met Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr 800 805 810 gat acc act gtg gat gac aat gag agc tat tac aag agt tac acc agc 2497 Asp Thr Thr Val Asp Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser 815 820 825 acc cag acc agc agc aag agc ttt ctc aag agc tat gac agc agc acc 2545 Thr Gln Thr Ser Ser Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr 830 835 840 agt gcc agt gag gcc tat ggg aag agt tac tgc act acc agc aac agc 2593 Ser Ala Ser Glu Ala Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser 845 850 855 860 agc att acc tat aag aag agt tac ggc agc acc agt agc tct gac acc 2641 Ser Ile Thr Tyr Lys Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr 865 870 875 tgc cag aag agt ttt gtc agc agc tgc act gac gag gaa cct gct gag 2689 Cys Gln Lys Ser Phe Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu 880 885 890 cct gaa gac atg gag cgc ttt gag gaa atg gtt gtg aaa gtg ctg atc 2737 Pro Glu Asp Met Glu Arg Phe Glu Glu Met Val Val Lys Val Leu Ile 895 900 905 aag ctg cag gcg gtg cag gcc atg tac cag ata agc cag gag gaa cac 2785 Lys Leu Gln Ala Val Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His 910 915 920 agc cag ctg caa gag cag atg gaa aag tta ctg gcc aag cag aaa gac 2833 Ser Gln Leu Gln Glu Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp 925 930 935 940 ctg aag gaa gag ctg gat gcc tgt gaa agg gag ttc aag gag tgc atg 2881 Leu Lys Glu Glu Leu Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met 945 950 955 gaa tgc ctt gaa aag ccc atg gcc ccc cag aac gac aag aat gag atc 2929 Glu Cys Leu Glu Lys Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile 960 965 970 aaa gaa ctg cag acc aag ctg cgg gag ctg cag ctg caa tac cag gct 2977 Lys Glu Leu Gln Thr Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala 975 980 985 agc atg gat gag cag ggg cag ctt ctg gta gtg cag gag cag ctg gag 3025 Ser Met Asp Glu Gln Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu 990 995 1000 ggg cag ctg cag tgc tgc cag gag gag ctc cgc cag ctc agg gag aag 3073 Gly Gln Leu Gln Cys Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys 1005 1010 1015 1020 agg cct tct gtt gtc aaa gaa gcc cgg ggg aag aat gct aat aag aac 3121 Arg Pro Ser Val Val Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn 1025 1030 1035 atg aac aag aat gcc aat ggg gtt aaa atg aaa aag gtg acc aag cca 3169 Met Asn Lys Asn Ala Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro 1040 1045 1050 tgc tcg gat act tct gag agc gac ctt gag acc aga aag aag atc agg 3217 Cys Ser Asp Thr Ser Glu Ser Asp Leu Glu Thr Arg Lys Lys Ile Arg 1055 1060 1065 agg aaa atg aag agg aca aag agg aag agg aga agg aag aag aca gtg 3265 Arg Lys Met Lys Arg Thr Lys Arg Lys Arg Arg Arg Lys Lys Thr Val 1070 1075 1080 aag agg agg aag atg acg ccg act ctt ccc ttg aaa gtc ccg aag aaa 3313 Lys Arg Arg Lys Met Thr Pro Thr Leu Pro Leu Lys Val Pro Lys Lys 1085 1090 1095 1100 ata acc ccc tca gac ttt ccg aga gca aaa aga aca tgt ttg ggt tgt 3361 Ile Thr Pro Ser Asp Phe Pro Arg Ala Lys Arg Thr Cys Leu Gly Cys 1105 1110 1115 gga agc cta tgg tat tct tgg cta ttg cag ctg tgg ctc tgt atg tgt 3409 Gly Ser Leu Trp Tyr Ser Trp Leu Leu Gln Leu Trp Leu Cys Met Cys 1120 1125 1130 tac cca aca tgc gac agc agg agt cag agt tct gcc tca tgg agt gat 3457 Tyr Pro Thr Cys Asp Ser Arg Ser Gln Ser Ser Ala Ser Trp Ser Asp 1135 1140 1145 ggc aga cct tgg cca gcg cga ggg cag atc ccc agt ggc cac cac cct 3505 Gly Arg Pro Trp Pro Ala Arg Gly Gln Ile Pro Ser Gly His His Pro 1150 1155 1160 cag ctt tgg gca gga cac act gtg cca gaa ccc tcc cca tat gtt cca 3553 Gln Leu Trp Ala Gly His Thr Val Pro Glu Pro Ser Pro Tyr Val Pro 1165 1170 1175 1180 tgt gtc ccc atc tcc tca gcc tca gtc acc cag gct gaa aag gct tgt 3601 Cys Val Pro Ile Ser Ser Ala Ser Val Thr Gln Ala Glu Lys Ala Cys 1185 1190 1195 ggg gag cgg ctg act tcc atc tcc tgc ctt gtg taa gaacctgagt 3647 Gly Glu Arg Leu Thr Ser Ile Ser Cys Leu Val 1200 1205 tccttgtaat taaatatcaa ctgaattaaa aaaaaaaaaa aaaaa 3692 8 1207 PRT Homo sapiens 8 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala Gly Trp Ser Cys 1 5 10 15 Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser Tyr Glu Ala Ser 20 25 30 Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly Ser Leu Glu Arg 35 40 45 Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu Pro Ala Leu Tyr 50 55 60 Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Glu 65 70 75 80 Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser Leu Ser Val Asn 85 90 95 Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu Glu Glu Leu Arg 100 105 110 Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu Thr Arg Glu Leu 115 120 125 Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln Gly Leu Leu Glu 130 135 140 Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val Phe Thr Lys Gln 145 150 155 160 Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg Glu Glu Ile Ser 165 170 175 Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu Ile Glu Gln Glu 180 185 190 Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg Gln Ala Ala Glu 195 200 205 Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser Leu Gln Glu Asp 210 215 220 Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu Arg Ile Arg Gly 225 230 235 240 Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu Met Glu Met Lys 245 250 255 Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp Tyr Ser Gly Leu 260 265 270 Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His Phe Leu Asn Glu 275 280 285 Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu Thr Gly Gln Leu 290 295 300 Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr Glu Arg Trp Leu 305 310 315 320 Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser Gln Thr Ser Glu 325 330 335 Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu Leu Arg Gln Gln 340 345 350 Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys Asn Lys Cys Gln 355 360 365 Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His Arg Gln Val Ser 370 375 380 Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys Cys Ala Gln Asn 385 390 395 400 Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr Gln Asn Glu Glu 405 410 415 Leu Lys Ser Arg Leu Cys Thr Leu Gln Lys Lys Tyr Asp Thr Ser Gln 420 425 430 Asp Glu Gln Asn Glu Leu Leu Lys Met Gln Leu Gln Leu Gln Thr Glu 435 440 445 Leu Arg Gln Leu Lys Val Met Lys Ser Thr Leu Val Glu Asn Gln Ser 450 455 460 Glu Lys Glu Leu Leu Cys Arg Leu Gln Lys Leu His Leu Gln His Gln 465 470 475 480 Asn Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu 485 490 495 Gln Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln His Leu Arg Asp 500 505 510 Thr Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His 515 520 525 Ala Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu 530 535 540 Leu Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu 545 550 555 560 Leu Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro 565 570 575 Glu Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg 580 585 590 Leu Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly 595 600 605 Gln Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met 610 615 620 Gln Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu 625 630 635 640 Pro Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr 645 650 655 Lys Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln 660 665 670 Glu Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu 675 680 685 Gln Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe 690 695 700 Gln Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser 705 710 715 720 Lys Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln 725 730 735 Ala Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu 740 745 750 Gln Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala 755 760 765 Asp Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser 770 775 780 Pro Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser 785 790 795 800 Met Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val 805 810 815 Asp Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser 820 825 830 Ser Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu 835 840 845 Ala Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr 850 855 860 Lys Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser 865 870 875 880 Phe Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met 885 890 895 Glu Arg Phe Glu Glu Met Val Val Lys Val Leu Ile Lys Leu Gln Ala 900 905 910 Val Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln 915 920 925 Glu Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu 930 935 940 Leu Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu 945 950 955 960 Lys Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln 965 970 975 Thr Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu 980 985 990 Gln Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln 995 1000 1005 Cys Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val 1010 1015 1020 Val Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn 1025 1030 1035 1040 Ala Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr 1045 1050 1055 Ser Glu Ser Asp Leu Glu Thr Arg Lys Lys Ile Arg Arg Lys Met Lys 1060 1065 1070 Arg Thr Lys Arg Lys Arg Arg Arg Lys Lys Thr Val Lys Arg Arg Lys 1075 1080 1085 Met Thr Pro Thr Leu Pro Leu Lys Val Pro Lys Lys Ile Thr Pro Ser 1090 1095 1100 Asp Phe Pro Arg Ala Lys Arg Thr Cys Leu Gly Cys Gly Ser Leu Trp 1105 1110 1115 1120 Tyr Ser Trp Leu Leu Gln Leu Trp Leu Cys Met Cys Tyr Pro Thr Cys 1125 1130 1135 Asp Ser Arg Ser Gln Ser Ser Ala Ser Trp Ser Asp Gly Arg Pro Trp 1140 1145 1150 Pro Ala Arg Gly Gln Ile Pro Ser Gly His His Pro Gln Leu Trp Ala 1155 1160 1165 Gly His Thr Val Pro Glu Pro Ser Pro Tyr Val Pro Cys Val Pro Ile 1170 1175 1180 Ser Ser Ala Ser Val Thr Gln Ala Glu Lys Ala Cys Gly Glu Arg Leu 1185 1190 1195 1200 Thr Ser Ile Ser Cys Leu Val 1205 9 3873 DNA Homo sapiens CDS (14)..(3637) 9 ggcacgagcg gtc atg gag gcg ggc gcc gga gcc ggc gcg gga gcc gcg 49 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala 1 5 10 ggc tgg agc tgc ccg ggc cca gga ccc aca gtg acc act cta ggc tcc 97 Gly Trp Ser Cys Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser 15 20 25 tat gag gct tcc gag ggc tgt gag agg aag aag ggc caa cgc tgg ggg 145 Tyr Glu Ala Ser Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly 30 35 40 tcc ctg gaa cga cgg ggg atg caa gct atg gag ggg gag gtg tta ctc 193 Ser Leu Glu Arg Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu 45 50 55 60 cca gct ctc tat gag gag gaa gag gaa gag gaa gag gag gaa gaa gag 241 Pro Ala Leu Tyr Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 65 70 75 gtg gaa gaa gaa gaa gaa caa gtg cag aaa ggt ggc agt gtt ggc tct 289 Val Glu Glu Glu Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser 80 85 90 ctg tca gtc aac aag cac cgg gga ctg agc ctc acg gag aca gag ctg 337 Leu Ser Val Asn Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu 95 100 105 gag gag ctg cgg gct cag gtg ctg cag ctg gtg gca gaa ctg gag gag 385 Glu Glu Leu Arg Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu 110 115 120 acc cgg gaa ctg gca ggg cag cat gag gat gac tcc ttg gag cta cag 433 Thr Arg Glu Leu Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln 125 130 135 140 ggg ctc ctg gag gat gaa cgg cta gcc agc gcc cag cag gca gag gtg 481 Gly Leu Leu Glu Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val 145 150 155 ttc acc aag cag atc cag cag ctc caa ggt gag ctg cgt tct cta cgg 529 Phe Thr Lys Gln Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg 160 165 170 gag gag att tcc ctg tta gag cat gag aaa gaa agc gaa ctt aag gaa 577 Glu Glu Ile Ser Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu 175 180 185 ata gaa cag gaa ttg cat ttg gcc cag gct gag atc cag agt ctg cgg 625 Ile Glu Gln Glu Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg 190 195 200 caa gca gca gag gat tcc gca act gaa cat gag agt gac ata gca tcc 673 Gln Ala Ala Glu Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser 205 210 215 220 ctg cag gag gat ctc tgc cgg atg cag aat gaa ctt gaa gac atg gaa 721 Leu Gln Glu Asp Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu 225 230 235 cgc att cgg gga gat tat gag atg gag atc gcc tcc ctc cgt gca gaa 769 Arg Ile Arg Gly Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu 240 245 250 atg gaa atg aag agc tct gaa cca tcc ggt agt tta ggt ctc tca gat 817 Met Glu Met Lys Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp 255 260 265 tac tct ggg tta caa gaa gaa ctg cag gag ctg cgg gaa cgc tac cat 865 Tyr Ser Gly Leu Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His 270 275 280 ttc ctg aat gag gaa tac cgg gcc ctg cag gag agc aac agc agc ctc 913 Phe Leu Asn Glu Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu 285 290 295 300 acg ggg cag ctt gca gat ctg gag agt gag agg aca cag aga gca aca 961 Thr Gly Gln Leu Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr 305 310 315 gag aga tgg ctg cag tcc caa aca ctg agt atg acg tca gca gag tct 1009 Glu Arg Trp Leu Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser 320 325 330 cag act tca gaa atg gat ttc tta gag cct gat cct gaa atg cag ttg 1057 Gln Thr Ser Glu Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu 335 340 345 tta cgg cag cag cta cgg gat gct gaa gag cag atg cat ggc atg aag 1105 Leu Arg Gln Gln Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys 350 355 360 aac aag tgt cag gaa ttg tgt tgt gag ttg gaa gag cta cag cat cat 1153 Asn Lys Cys Gln Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His 365 370 375 380 cgc cag gtc agt gag gag gag cag agg cgg ctg cag agg gag ctc aag 1201 Arg Gln Val Ser Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys 385 390 395 tgt gct cag aat gag gtg ctt cgg ttt cag acc tcc cac agt gtc acc 1249 Cys Ala Gln Asn Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr 400 405 410 cag aat gag gag ctg aag tcc aga ctc tgt acc ctg cag aaa aaa tat 1297 Gln Asn Glu Glu Leu Lys Ser Arg Leu Cys Thr Leu Gln Lys Lys Tyr 415 420 425 gat act agc cag gat gag cag aac gag ctc ttg aag atg cag ctg caa 1345 Asp Thr Ser Gln Asp Glu Gln Asn Glu Leu Leu Lys Met Gln Leu Gln 430 435 440 ctt cag act gag ctc cgg cag ctc aaa gtc atg aaa tcc aca ctt gta 1393 Leu Gln Thr Glu Leu Arg Gln Leu Lys Val Met Lys Ser Thr Leu Val 445 450 455 460 gaa aac cag agt gag aag gag tta ctg tgc cgg ctg cag aag ctg cac 1441 Glu Asn Gln Ser Glu Lys Glu Leu Leu Cys Arg Leu Gln Lys Leu His 465 470 475 ctc cag cac cag aac gtc aca tgt gag aag gaa aag ctg ctg gaa cgg 1489 Leu Gln His Gln Asn Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg 480 485 490 cag cag cag ctg cag gag gag ctg cag tgc cat gag gca gag ctg cag 1537 Gln Gln Gln Leu Gln Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln 495 500 505 cac ctc agg gat acg gtg gcc tcc ttc aaa gag agc aat gag aag gac 1585 His Leu Arg Asp Thr Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp 510 515 520 aca gag acg cac gct cag ctt cag gag atg aag cag ctg tac cag gcc 1633 Thr Glu Thr His Ala Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala 525 530 535 540 agc aag gac gag ctg gag cgg cag aag cac atg tat gac cag ctg gag 1681 Ser Lys Asp Glu Leu Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu 545 550 555 cag gac ctc ctg ctc tgc cag ctg gag ctg aaa gag ctc aag gcc tcc 1729 Gln Asp Leu Leu Leu Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser 560 565 570 cac ccc att ccg gag gac aaa gga aag tgt gct aat aag tgt gac aca 1777 His Pro Ile Pro Glu Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr 575 580 585 ctg ctg tcc aga ctg aca gaa ttg cag gaa aag tac aag gcc agc cag 1825 Leu Leu Ser Arg Leu Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln 590 595 600 aag gag atg ggg cag ctg cag atg gag cag tgt gag ctc ctg gag gat 1873 Lys Glu Met Gly Gln Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp 605 610 615 620 cag agg agg atg cag gag gag cag ggc cag ctg cag gaa gag ctg cac 1921 Gln Arg Arg Met Gln Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His 625 630 635 agg ctc aca ctg cca ctg cca aag agt ggc ctc tta ctc aag agt cag 1969 Arg Leu Thr Leu Pro Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln 640 645 650 gag cta ctc acc aag tta gaa gac ctg tgt gag ctg cag ctg ctc tac 2017 Glu Leu Leu Thr Lys Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr 655 660 665 caa ggc atg cag gag gaa cag aag aag ctg ata cag aac caa gac tgt 2065 Gln Gly Met Gln Glu Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys 670 675 680 gta tta aaa gaa caa tta gag atc cac gaa gag ctg cga cgt ttc aaa 2113 Val Leu Lys Glu Gln Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys 685 690 695 700 gag tct cat ttc cag gaa gtg ttg gag aat ccc gat gat tcc aaa ttg 2161 Glu Ser His Phe Gln Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu 705 710 715 gct aag tcc tcc aaa tgt aat cga aac aag caa tcc aag ctg ctc atg 2209 Ala Lys Ser Ser Lys Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met 720 725 730 gag cag atg cag gcc ctg cag gtg atg tat gac gcc ggt cag gcg aag 2257 Glu Gln Met Gln Ala Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys 735 740 745 cag gag ctc ttg cag caa gag caa ggg agg ctc cta gag gag cgg aag 2305 Gln Glu Leu Leu Gln Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys 750 755 760 agg ctg cag gca gac ttg cag ctc tgc ctg gaa gaa atg cag ctg ctt 2353 Arg Leu Gln Ala Asp Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu 765 770 775 780 caa gtc cag tcc cct tct ata aaa atg agc ctt gag tcc tac ggg aag 2401 Gln Val Gln Ser Pro Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys 785 790 795 agc tat ggt agc atg gtc ccc agc aat gag aac tgt cgc aag act tat 2449 Ser Tyr Gly Ser Met Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr 800 805 810 gat acc act gtg gat gac aat gag agc tat tac aag agt tac acc agc 2497 Asp Thr Thr Val Asp Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser 815 820 825 acc cag acc agc agc aag agc ttt ctc aag agc tat gac agc agc acc 2545 Thr Gln Thr Ser Ser Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr 830 835 840 agt gcc agt gag gcc tat ggg aag agt tac tgc act acc agc aac agc 2593 Ser Ala Ser Glu Ala Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser 845 850 855 860 agc att acc tat aag aag agt tac ggc agc acc agt agc tct gac acc 2641 Ser Ile Thr Tyr Lys Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr 865 870 875 tgc cag aag agt ttt gtc agc agc tgc act gac gag gaa cct gct gag 2689 Cys Gln Lys Ser Phe Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu 880 885 890 cct gaa gac atg gag cgc ttt gag gaa atg gtt gtg aaa gtg ctg atc 2737 Pro Glu Asp Met Glu Arg Phe Glu Glu Met Val Val Lys Val Leu Ile 895 900 905 aag ctg cag gcg gtg cag gcc atg tac cag ata agc cag gag gaa cac 2785 Lys Leu Gln Ala Val Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His 910 915 920 agc cag ctg caa gag cag atg gaa aag tta ctg gcc aag cag aaa gac 2833 Ser Gln Leu Gln Glu Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp 925 930 935 940 ctg aag gaa gag ctg gat gcc tgt gaa agg gag ttc aag gag tgc atg 2881 Leu Lys Glu Glu Leu Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met 945 950 955 gaa tgc ctt gaa aag ccc atg gcc ccc cag aac gac aag aat gag atc 2929 Glu Cys Leu Glu Lys Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile 960 965 970 aaa gaa ctg cag acc aag ctg cgg gag ctg cag ctg caa tac cag gct 2977 Lys Glu Leu Gln Thr Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala 975 980 985 agc atg gat gag cag ggg cag ctt ctg gta gtg cag gag cag ctg gag 3025 Ser Met Asp Glu Gln Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu 990 995 1000 ggg cag ctg cag tgc tgc cag gag gag ctc cgc cag ctc agg gag aag 3073 Gly Gln Leu Gln Cys Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys 1005 1010 1015 1020 agg cct tct gtt gtc aaa gaa gcc cgg ggg aag aat gct aat aag aac 3121 Arg Pro Ser Val Val Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn 1025 1030 1035 atg aac aag aat gcc aat ggg gtt aaa atg aaa aag gtg acc aag cca 3169 Met Asn Lys Asn Ala Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro 1040 1045 1050 tgc tcg gat act tct gag agc gac ctt gag acc aga aag agt ctg gag 3217 Cys Ser Asp Thr Ser Glu Ser Asp Leu Glu Thr Arg Lys Ser Leu Glu 1055 1060 1065 gta gtg ctg tac tac aag gcc agc cag agg aaa tta gat gga cta gca 3265 Val Val Leu Tyr Tyr Lys Ala Ser Gln Arg Lys Leu Asp Gly Leu Ala 1070 1075 1080 aaa gag gag gaa aag aaa gag gag atg gag gag gaa aaa aag gaa gtg 3313 Lys Glu Glu Glu Lys Lys Glu Glu Met Glu Glu Glu Lys Lys Glu Val 1085 1090 1095 1100 aaa gag gaa gca aag gag cag tgt ggg gat gag cta gtt gct gag cca 3361 Lys Glu Glu Ala Lys Glu Gln Cys Gly Asp Glu Leu Val Ala Glu Pro 1105 1110 1115 gca gat cct gag gaa gct aaa tcc aca gaa gat cag gag gaa aat gaa 3409 Ala Asp Pro Glu Glu Ala Lys Ser Thr Glu Asp Gln Glu Glu Asn Glu 1120 1125 1130 gag gac aaa gag gaa gag gag aag gaa gaa gac agt gaa gag gag gaa 3457 Glu Asp Lys Glu Glu Glu Glu Lys Glu Glu Asp Ser Glu Glu Glu Glu 1135 1140 1145 gat gac gcc gac tct tcc ctt gaa agt ccc gaa gaa aat aac ccc ctc 3505 Asp Asp Ala Asp Ser Ser Leu Glu Ser Pro Glu Glu Asn Asn Pro Leu 1150 1155 1160 aga ctt tcc gag agc aaa aag aac atg ttt ggg ttg tgg aag cct atg 3553 Arg Leu Ser Glu Ser Lys Lys Asn Met Phe Gly Leu Trp Lys Pro Met 1165 1170 1175 1180 gta ttc ttg gct att gca gct gtg gct ctg tat gtg tta ccc aac atg 3601 Val Phe Leu Ala Ile Ala Ala Val Ala Leu Tyr Val Leu Pro Asn Met 1185 1190 1195 cga cag cag gag tca gag ttc tgc ctc atg gag tga tggcagacct 3647 Arg Gln Gln Glu Ser Glu Phe Cys Leu Met Glu 1200 1205 tggccagcgc gagggcagat ccccagtggc caccaccctc agctttgggc aggacacact 3707 gtgccagaac cctccccata tgttccatgt gtccccatct cctcagcctc agtcacccag 3767 gctgaaaagg cttgtgggga gcggctgact tccatctcct gccttgtgta agaacctgag 3827 ttccttgtaa ttaaatatca actgaattaa aaaaaaaaaa aaaaaa 3873 10 1207 PRT Homo sapiens 10 Met Glu Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala Gly Trp Ser Cys 1 5 10 15 Pro Gly Pro Gly Pro Thr Val Thr Thr Leu Gly Ser Tyr Glu Ala Ser 20 25 30 Glu Gly Cys Glu Arg Lys Lys Gly Gln Arg Trp Gly Ser Leu Glu Arg 35 40 45 Arg Gly Met Gln Ala Met Glu Gly Glu Val Leu Leu Pro Ala Leu Tyr 50 55 60 Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Glu 65 70 75 80 Glu Glu Gln Val Gln Lys Gly Gly Ser Val Gly Ser Leu Ser Val Asn 85 90 95 Lys His Arg Gly Leu Ser Leu Thr Glu Thr Glu Leu Glu Glu Leu Arg 100 105 110 Ala Gln Val Leu Gln Leu Val Ala Glu Leu Glu Glu Thr Arg Glu Leu 115 120 125 Ala Gly Gln His Glu Asp Asp Ser Leu Glu Leu Gln Gly Leu Leu Glu 130 135 140 Asp Glu Arg Leu Ala Ser Ala Gln Gln Ala Glu Val Phe Thr Lys Gln 145 150 155 160 Ile Gln Gln Leu Gln Gly Glu Leu Arg Ser Leu Arg Glu Glu Ile Ser 165 170 175 Leu Leu Glu His Glu Lys Glu Ser Glu Leu Lys Glu Ile Glu Gln Glu 180 185 190 Leu His Leu Ala Gln Ala Glu Ile Gln Ser Leu Arg Gln Ala Ala Glu 195 200 205 Asp Ser Ala Thr Glu His Glu Ser Asp Ile Ala Ser Leu Gln Glu Asp 210 215 220 Leu Cys Arg Met Gln Asn Glu Leu Glu Asp Met Glu Arg Ile Arg Gly 225 230 235 240 Asp Tyr Glu Met Glu Ile Ala Ser Leu Arg Ala Glu Met Glu Met Lys 245 250 255 Ser Ser Glu Pro Ser Gly Ser Leu Gly Leu Ser Asp Tyr Ser Gly Leu 260 265 270 Gln Glu Glu Leu Gln Glu Leu Arg Glu Arg Tyr His Phe Leu Asn Glu 275 280 285 Glu Tyr Arg Ala Leu Gln Glu Ser Asn Ser Ser Leu Thr Gly Gln Leu 290 295 300 Ala Asp Leu Glu Ser Glu Arg Thr Gln Arg Ala Thr Glu Arg Trp Leu 305 310 315 320 Gln Ser Gln Thr Leu Ser Met Thr Ser Ala Glu Ser Gln Thr Ser Glu 325 330 335 Met Asp Phe Leu Glu Pro Asp Pro Glu Met Gln Leu Leu Arg Gln Gln 340 345 350 Leu Arg Asp Ala Glu Glu Gln Met His Gly Met Lys Asn Lys Cys Gln 355 360 365 Glu Leu Cys Cys Glu Leu Glu Glu Leu Gln His His Arg Gln Val Ser 370 375 380 Glu Glu Glu Gln Arg Arg Leu Gln Arg Glu Leu Lys Cys Ala Gln Asn 385 390 395 400 Glu Val Leu Arg Phe Gln Thr Ser His Ser Val Thr Gln Asn Glu Glu 405 410 415 Leu Lys Ser Arg Leu Cys Thr Leu Gln Lys Lys Tyr Asp Thr Ser Gln 420 425 430 Asp Glu Gln Asn Glu Leu Leu Lys Met Gln Leu Gln Leu Gln Thr Glu 435 440 445 Leu Arg Gln Leu Lys Val Met Lys Ser Thr Leu Val Glu Asn Gln Ser 450 455 460 Glu Lys Glu Leu Leu Cys Arg Leu Gln Lys Leu His Leu Gln His Gln 465 470 475 480 Asn Val Thr Cys Glu Lys Glu Lys Leu Leu Glu Arg Gln Gln Gln Leu 485 490 495 Gln Glu Glu Leu Gln Cys His Glu Ala Glu Leu Gln His Leu Arg Asp 500 505 510 Thr Val Ala Ser Phe Lys Glu Ser Asn Glu Lys Asp Thr Glu Thr His 515 520 525 Ala Gln Leu Gln Glu Met Lys Gln Leu Tyr Gln Ala Ser Lys Asp Glu 530 535 540 Leu Glu Arg Gln Lys His Met Tyr Asp Gln Leu Glu Gln Asp Leu Leu 545 550 555 560 Leu Cys Gln Leu Glu Leu Lys Glu Leu Lys Ala Ser His Pro Ile Pro 565 570 575 Glu Asp Lys Gly Lys Cys Ala Asn Lys Cys Asp Thr Leu Leu Ser Arg 580 585 590 Leu Thr Glu Leu Gln Glu Lys Tyr Lys Ala Ser Gln Lys Glu Met Gly 595 600 605 Gln Leu Gln Met Glu Gln Cys Glu Leu Leu Glu Asp Gln Arg Arg Met 610 615 620 Gln Glu Glu Gln Gly Gln Leu Gln Glu Glu Leu His Arg Leu Thr Leu 625 630 635 640 Pro Leu Pro Lys Ser Gly Leu Leu Leu Lys Ser Gln Glu Leu Leu Thr 645 650 655 Lys Leu Glu Asp Leu Cys Glu Leu Gln Leu Leu Tyr Gln Gly Met Gln 660 665 670 Glu Glu Gln Lys Lys Leu Ile Gln Asn Gln Asp Cys Val Leu Lys Glu 675 680 685 Gln Leu Glu Ile His Glu Glu Leu Arg Arg Phe Lys Glu Ser His Phe 690 695 700 Gln Glu Val Leu Glu Asn Pro Asp Asp Ser Lys Leu Ala Lys Ser Ser 705 710 715 720 Lys Cys Asn Arg Asn Lys Gln Ser Lys Leu Leu Met Glu Gln Met Gln 725 730 735 Ala Leu Gln Val Met Tyr Asp Ala Gly Gln Ala Lys Gln Glu Leu Leu 740 745 750 Gln Gln Glu Gln Gly Arg Leu Leu Glu Glu Arg Lys Arg Leu Gln Ala 755 760 765 Asp Leu Gln Leu Cys Leu Glu Glu Met Gln Leu Leu Gln Val Gln Ser 770 775 780 Pro Ser Ile Lys Met Ser Leu Glu Ser Tyr Gly Lys Ser Tyr Gly Ser 785 790 795 800 Met Val Pro Ser Asn Glu Asn Cys Arg Lys Thr Tyr Asp Thr Thr Val 805 810 815 Asp Asp Asn Glu Ser Tyr Tyr Lys Ser Tyr Thr Ser Thr Gln Thr Ser 820 825 830 Ser Lys Ser Phe Leu Lys Ser Tyr Asp Ser Ser Thr Ser Ala Ser Glu 835 840 845 Ala Tyr Gly Lys Ser Tyr Cys Thr Thr Ser Asn Ser Ser Ile Thr Tyr 850 855 860 Lys Lys Ser Tyr Gly Ser Thr Ser Ser Ser Asp Thr Cys Gln Lys Ser 865 870 875 880 Phe Val Ser Ser Cys Thr Asp Glu Glu Pro Ala Glu Pro Glu Asp Met 885 890 895 Glu Arg Phe Glu Glu Met Val Val Lys Val Leu Ile Lys Leu Gln Ala 900 905 910 Val Gln Ala Met Tyr Gln Ile Ser Gln Glu Glu His Ser Gln Leu Gln 915 920 925 Glu Gln Met Glu Lys Leu Leu Ala Lys Gln Lys Asp Leu Lys Glu Glu 930 935 940 Leu Asp Ala Cys Glu Arg Glu Phe Lys Glu Cys Met Glu Cys Leu Glu 945 950 955 960 Lys Pro Met Ala Pro Gln Asn Asp Lys Asn Glu Ile Lys Glu Leu Gln 965 970 975 Thr Lys Leu Arg Glu Leu Gln Leu Gln Tyr Gln Ala Ser Met Asp Glu 980 985 990 Gln Gly Gln Leu Leu Val Val Gln Glu Gln Leu Glu Gly Gln Leu Gln 995 1000 1005 Cys Cys Gln Glu Glu Leu Arg Gln Leu Arg Glu Lys Arg Pro Ser Val 1010 1015 1020 Val Lys Glu Ala Arg Gly Lys Asn Ala Asn Lys Asn Met Asn Lys Asn 1025 1030 1035 1040 Ala Asn Gly Val Lys Met Lys Lys Val Thr Lys Pro Cys Ser Asp Thr 1045 1050 1055 Ser Glu Ser Asp Leu Glu Thr Arg Lys Ser Leu Glu Val Val Leu Tyr 1060 1065 1070 Tyr Lys Ala Ser Gln Arg Lys Leu Asp Gly Leu Ala Lys Glu Glu Glu 1075 1080 1085 Lys Lys Glu Glu Met Glu Glu Glu Lys Lys Glu Val Lys Glu Glu Ala 1090 1095 1100 Lys Glu Gln Cys Gly Asp Glu Leu Val Ala Glu Pro Ala Asp Pro Glu 1105 1110 1115 1120 Glu Ala Lys Ser Thr Glu Asp Gln Glu Glu Asn Glu Glu Asp Lys Glu 1125 1130 1135 Glu Glu Glu Lys Glu Glu Asp Ser Glu Glu Glu Glu Asp Asp Ala Asp 1140 1145 1150 Ser Ser Leu Glu Ser Pro Glu Glu Asn Asn Pro Leu Arg Leu Ser Glu 1155 1160 1165 Ser Lys Lys Asn Met Phe Gly Leu Trp Lys Pro Met Val Phe Leu Ala 1170 1175 1180 Ile Ala Ala Val Ala Leu Tyr Val Leu Pro Asn Met Arg Gln Gln Glu 1185 1190 1195 1200 Ser Glu Phe Cys Leu Met Glu 1205 11 3847 DNA Homo sapiens CDS (211)..(2883) 11 gcggaggtgg agtacaacgg gggcttccac ctggccatcg acgtggacct ggtcttcggc 60 aagtccgcct acttgtttgt caagctgtcc cgcgtggtgg ggaggctgcg cttggtcttt 120 acgcgcgtgc ccttcaccca ctggttcttc tccttcgtgg aagacccgct gatcgacttc 180 gaggtgcgct cgcagtttga agggcggccc atg ccc cag ctc acc tcc atc atc 234 Met Pro Gln Leu Thr Ser Ile Ile 1 5 gtc aac cag ctc aag aag atc atc aag cgc aag cac acc cta ccg aat 282 Val Asn Gln Leu Lys Lys Ile Ile Lys Arg Lys His Thr Leu Pro Asn 10 15 20 tac aag atc agg ttt aag ccg ttt ttt cca tac cag acc ttg caa gga 330 Tyr Lys Ile Arg Phe Lys Pro Phe Phe Pro Tyr Gln Thr Leu Gln Gly 25 30 35 40 ttt gaa gaa gat gaa gag cat atc cat ata caa caa tgg gca ctt act 378 Phe Glu Glu Asp Glu Glu His Ile His Ile Gln Gln Trp Ala Leu Thr 45 50 55 gaa ggc cgt ctt aaa gtt acg ttg tta gaa tgt agc agg tta ctc att 426 Glu Gly Arg Leu Lys Val Thr Leu Leu Glu Cys Ser Arg Leu Leu Ile 60 65 70 ttt gga tcc tat gac aga gag gca aat gtt cat tgc aca ctt gag tta 474 Phe Gly Ser Tyr Asp Arg Glu Ala Asn Val His Cys Thr Leu Glu Leu 75 80 85 agc agt agt gtt tgg gaa gaa aaa cag agg agt tct att aag acg gtt 522 Ser Ser Ser Val Trp Glu Glu Lys Gln Arg Ser Ser Ile Lys Thr Val 90 95 100 gaa tta ata aaa gga aat tta caa agt gtt gga ctt aca ctt cgt ctt 570 Glu Leu Ile Lys Gly Asn Leu Gln Ser Val Gly Leu Thr Leu Arg Leu 105 110 115 120 gtc cag tca act gat ggg tat gct ggg cac gtc atc att gaa act gtg 618 Val Gln Ser Thr Asp Gly Tyr Ala Gly His Val Ile Ile Glu Thr Val 125 130 135 gct cca aac tcg cct gct gca att gca gat ctt cag cgg gga gat cga 666 Ala Pro Asn Ser Pro Ala Ala Ile Ala Asp Leu Gln Arg Gly Asp Arg 140 145 150 ctt atc gcc att gga ggt gtg aaa atc aca tca aca ctg caa gtg ttg 714 Leu Ile Ala Ile Gly Gly Val Lys Ile Thr Ser Thr Leu Gln Val Leu 155 160 165 aag ctt atc aag cag gct ggt gac cga gtc ctg gtg tac tat gaa agg 762 Lys Leu Ile Lys Gln Ala Gly Asp Arg Val Leu Val Tyr Tyr Glu Arg 170 175 180 cct gtt ggc cag agt aat caa ggt gca gtg ctg caa gat aac ttt ggc 810 Pro Val Gly Gln Ser Asn Gln Gly Ala Val Leu Gln Asp Asn Phe Gly 185 190 195 200 cag ttg gaa gaa aac ttt ttg tca agc tca tgc caa tcg ggt tat gaa 858 Gln Leu Glu Glu Asn Phe Leu Ser Ser Ser Cys Gln Ser Gly Tyr Glu 205 210 215 gag gaa gct gcc ggg ttg aca gta gat act gaa agt aga gag ctg gat 906 Glu Glu Ala Ala Gly Leu Thr Val Asp Thr Glu Ser Arg Glu Leu Asp 220 225 230 tct gaa ttt gaa gac ttg gca agt gat gtc aga gca caa aat gag ttc 954 Ser Glu Phe Glu Asp Leu Ala Ser Asp Val Arg Ala Gln Asn Glu Phe 235 240 245 aaa gat gag gca caa tca tta agt cat agt ccc aaa cgt gtt cca aca 1002 Lys Asp Glu Ala Gln Ser Leu Ser His Ser Pro Lys Arg Val Pro Thr 250 255 260 aca ctt tct att aaa ccc ctt gga gct ata tca cca gtt tta aac cgt 1050 Thr Leu Ser Ile Lys Pro Leu Gly Ala Ile Ser Pro Val Leu Asn Arg 265 270 275 280 aaa tta gct gta gga agt cac cca cta cca ccg aaa att cag tcc aaa 1098 Lys Leu Ala Val Gly Ser His Pro Leu Pro Pro Lys Ile Gln Ser Lys 285 290 295 gat gga aat aaa cct cca ccc cta aaa act tct gag ata aca gac cca 1146 Asp Gly Asn Lys Pro Pro Pro Leu Lys Thr Ser Glu Ile Thr Asp Pro 300 305 310 gca caa gtg tca aaa cca acc caa gga tct gct ttc aaa cca cct gtg 1194 Ala Gln Val Ser Lys Pro Thr Gln Gly Ser Ala Phe Lys Pro Pro Val 315 320 325 cca cca cga cca caa gcg aaa gtt cct ttg cct tcc gcc gat gct cca 1242 Pro Pro Arg Pro Gln Ala Lys Val Pro Leu Pro Ser Ala Asp Ala Pro 330 335 340 aat cag gca gaa cca gat gtt ctc gtt gaa aag cca gag aag gtg gtg 1290 Asn Gln Ala Glu Pro Asp Val Leu Val Glu Lys Pro Glu Lys Val Val 345 350 355 360 cca cct cct ctt gta gat aaa tct gct gaa aag caa gca aaa aat gtg 1338 Pro Pro Pro Leu Val Asp Lys Ser Ala Glu Lys Gln Ala Lys Asn Val 365 370 375 gat gcc ata gac gat gca gct gca cct aag caa ttt tta gca aag caa 1386 Asp Ala Ile Asp Asp Ala Ala Ala Pro Lys Gln Phe Leu Ala Lys Gln 380 385 390 gaa gtg gcc aaa gat gtc act tca gaa act ttc tgc cct act aag gac 1434 Glu Val Ala Lys Asp Val Thr Ser Glu Thr Phe Cys Pro Thr Lys Asp 395 400 405 agt tcg gac gac cgt caa aca tgg gaa tca tca gaa att ctt tat cgt 1482 Ser Ser Asp Asp Arg Gln Thr Trp Glu Ser Ser Glu Ile Leu Tyr Arg 410 415 420 aat aag cta gga aaa tgg aca aga acc aga gca tcc tgt ttg ttt gac 1530 Asn Lys Leu Gly Lys Trp Thr Arg Thr Arg Ala Ser Cys Leu Phe Asp 425 430 435 440 ata gaa gcc tgt cac agg tac tta aac att gca ttg tgg tgc agg gat 1578 Ile Glu Ala Cys His Arg Tyr Leu Asn Ile Ala Leu Trp Cys Arg Asp 445 450 455 cct ttc aag ttg gga ggt ctc atc tgt ttg ggg cat gtt agt tta aaa 1626 Pro Phe Lys Leu Gly Gly Leu Ile Cys Leu Gly His Val Ser Leu Lys 460 465 470 ctt gaa gat gtg gct tta gga tgc cta gct aca tca aac acg gaa tac 1674 Leu Glu Asp Val Ala Leu Gly Cys Leu Ala Thr Ser Asn Thr Glu Tyr 475 480 485 ctt tcc aaa ttg aga ctg gaa gcc ccc tca cct aag gct ata gtc act 1722 Leu Ser Lys Leu Arg Leu Glu Ala Pro Ser Pro Lys Ala Ile Val Thr 490 495 500 aga acc gca cta cgc aat ctg agt atg caa aag gga ttc aat gac aaa 1770 Arg Thr Ala Leu Arg Asn Leu Ser Met Gln Lys Gly Phe Asn Asp Lys 505 510 515 520 ttt tgc tat ggt gac att act att cac ttc aaa tat ttg aaa gaa gga 1818 Phe Cys Tyr Gly Asp Ile Thr Ile His Phe Lys Tyr Leu Lys Glu Gly 525 530 535 gaa tca gac cac cat gta gtt act aac gta gaa aaa gaa aaa gaa ccc 1866 Glu Ser Asp His His Val Val Thr Asn Val Glu Lys Glu Lys Glu Pro 540 545 550 cat ttg gtt gaa gaa gtt tct gtt ctc cct aaa gag gag caa ttt gtt 1914 His Leu Val Glu Glu Val Ser Val Leu Pro Lys Glu Glu Gln Phe Val 555 560 565 gga cag atg ggt tta aca gaa aac aaa cac agt ttt cag gat act cag 1962 Gly Gln Met Gly Leu Thr Glu Asn Lys His Ser Phe Gln Asp Thr Gln 570 575 580 ttc cag aac cca aca tgg tgt gac tac tgt aag aaa aaa gtt tgg act 2010 Phe Gln Asn Pro Thr Trp Cys Asp Tyr Cys Lys Lys Lys Val Trp Thr 585 590 595 600 aaa gca gct tcc cag tgt atg ttt tgt gct tat gtt tgc cat aaa aaa 2058 Lys Ala Ala Ser Gln Cys Met Phe Cys Ala Tyr Val Cys His Lys Lys 605 610 615 tgt caa gaa aag tgt cta gct gag act tct gtt tgt gga gca act gat 2106 Cys Gln Glu Lys Cys Leu Ala Glu Thr Ser Val Cys Gly Ala Thr Asp 620 625 630 agg cga ata gac agg aca ctg aaa aac ctt agg ctg gaa gga cag gaa 2154 Arg Arg Ile Asp Arg Thr Leu Lys Asn Leu Arg Leu Glu Gly Gln Glu 635 640 645 acc ctc tta ggc ctg cct cct cgt gtt gat gct gaa gct agc aag tca 2202 Thr Leu Leu Gly Leu Pro Pro Arg Val Asp Ala Glu Ala Ser Lys Ser 650 655 660 gtc aat aaa aca aca ggt ttg aca agg cat att atc aat act agt tct 2250 Val Asn Lys Thr Thr Gly Leu Thr Arg His Ile Ile Asn Thr Ser Ser 665 670 675 680 cgt tta tta aat ttg cgt caa gtc tct aaa act cgc ctt tct gaa cca 2298 Arg Leu Leu Asn Leu Arg Gln Val Ser Lys Thr Arg Leu Ser Glu Pro 685 690 695 gga acc gat ctc gta gaa cct tca cca aaa cac aca ccc aac acg tca 2346 Gly Thr Asp Leu Val Glu Pro Ser Pro Lys His Thr Pro Asn Thr Ser 700 705 710 gac aac gaa ggc agt gac acg gag gtc tgt ggt cca aac agt cct tct 2394 Asp Asn Glu Gly Ser Asp Thr Glu Val Cys Gly Pro Asn Ser Pro Ser 715 720 725 aaa cgg gga aac agc aca gga ata aag tta gtg aga aaa gag ggt ggt 2442 Lys Arg Gly Asn Ser Thr Gly Ile Lys Leu Val Arg Lys Glu Gly Gly 730 735 740 ctg gat gac agt gtt ttc att gca gtt aaa gaa att ggt cgt gat ctg 2490 Leu Asp Asp Ser Val Phe Ile Ala Val Lys Glu Ile Gly Arg Asp Leu 745 750 755 760 tac agg ggc ttg cct aca gag gaa agg atc cag aaa cta gag ttc atg 2538 Tyr Arg Gly Leu Pro Thr Glu Glu Arg Ile Gln Lys Leu Glu Phe Met 765 770 775 ttg gat aag cta cag aat gaa att gat cag gag ttg gaa cac aat aat 2586 Leu Asp Lys Leu Gln Asn Glu Ile Asp Gln Glu Leu Glu His Asn Asn 780 785 790 tcc ctt gtt aga gaa gaa aaa gag aca act gat aca agg aaa aaa tca 2634 Ser Leu Val Arg Glu Glu Lys Glu Thr Thr Asp Thr Arg Lys Lys Ser 795 800 805 ctt ctt tct gct gcc tta gct aaa tca ggt gaa agg cta caa gct cta 2682 Leu Leu Ser Ala Ala Leu Ala Lys Ser Gly Glu Arg Leu Gln Ala Leu 810 815 820 aca ctt ctt atg att cac tac aga gca ggc att gaa gat ata gaa act 2730 Thr Leu Leu Met Ile His Tyr Arg Ala Gly Ile Glu Asp Ile Glu Thr 825 830 835 840 tta gaa agt ctg tct tta gac cag cac tcc aaa aaa ata agc aag tac 2778 Leu Glu Ser Leu Ser Leu Asp Gln His Ser Lys Lys Ile Ser Lys Tyr 845 850 855 aca gat gat aca gaa gaa gac ctt gat aat gaa ata agc caa cta ata 2826 Thr Asp Asp Thr Glu Glu Asp Leu Asp Asn Glu Ile Ser Gln Leu Ile 860 865 870 gac tct cag cca ttc agc agc ata tca gat gac tta ttt ggc cca tcc 2874 Asp Ser Gln Pro Phe Ser Ser Ile Ser Asp Asp Leu Phe Gly Pro Ser 875 880 885 gag tct gtg tagcagacag gtctatttaa actttcaaat gaacagggta 2923 Glu Ser Val 890 aagttgcatc taaagtacca cagatacaac catgtttaaa tcctcgtatg cactctggcc 2983 tgcttctcca gttacttgct tgtgtaagaa caaaaatgag aaaggttgtt ttccagtaaa 3043 aacatgacca gcttactaat tggttgtttt ggattgcatt tatagctatg cttttttggg 3103 tttatactgg gaatttattt ttactaaatt atttaacttt tctaattatg taattatgta 3163 agctagcttt tcatgtttat gtatgtatgg tgtccccttg tgttattttt cttcctcttg 3223 gtttttgaat tagtgttaaa tagaatactg tctagattct taaaatattt tcatttccat 3283 catggttata acaaatttgc tgcatgccca aactgacaac agcantcact gagggaacag 3343 gttttgaatc tttcttttgt gttatgaagt ttatcgtctc tacttgcttg agatttttgt 3403 tattttgggg gtttgggggt gctttttgtt ttgtttttgc caaatgtaac atgaaagcag 3463 atgctgcagc tttagtctgt tatgctgatt tagtaaaaaa aaatttttta catatattgc 3523 ttgctttcga tgcttctgtg aaattttttt ctaaagcttt tgtgcagctg tatggtaaaa 3583 atatggtgat taatttgaag agcttacatt gaaagacaat gtaataggaa ataaatgtag 3643 attgcagttg gtcaagaatt ttgtagagag gataacaaga cttaattact gaaaaacagt 3703 aacatagcat tttgaaatat aatcttttaa aatattgatg ctttcctttt aaatggaaat 3763 ttaaatttta taattaaaag tttaaacatt tatgataatt ttcctcatca gttctcccat 3823 aggaaataaa gcatgtgaaa gggt 3847 12 891 PRT Homo sapiens 12 Met Pro Gln Leu Thr Ser Ile Ile Val Asn Gln Leu Lys Lys Ile Ile 1 5 10 15 Lys Arg Lys His Thr Leu Pro Asn Tyr Lys Ile Arg Phe Lys Pro Phe 20 25 30 Phe Pro Tyr Gln Thr Leu Gln Gly Phe Glu Glu Asp Glu Glu His Ile 35 40 45 His Ile Gln Gln Trp Ala Leu Thr Glu Gly Arg Leu Lys Val Thr Leu 50 55 60 Leu Glu Cys Ser Arg Leu Leu Ile Phe Gly Ser Tyr Asp Arg Glu Ala 65 70 75 80 Asn Val His Cys Thr Leu Glu Leu Ser Ser Ser Val Trp Glu Glu Lys 85 90 95 Gln Arg Ser Ser Ile Lys Thr Val Glu Leu Ile Lys Gly Asn Leu Gln 100 105 110 Ser Val Gly Leu Thr Leu Arg Leu Val Gln Ser Thr Asp Gly Tyr Ala 115 120 125 Gly His Val Ile Ile Glu Thr Val Ala Pro Asn Ser Pro Ala Ala Ile 130 135 140 Ala Asp Leu Gln Arg Gly Asp Arg Leu Ile Ala Ile Gly Gly Val Lys 145 150 155 160 Ile Thr Ser Thr Leu Gln Val Leu Lys Leu Ile Lys Gln Ala Gly Asp 165 170 175 Arg Val Leu Val Tyr Tyr Glu Arg Pro Val Gly Gln Ser Asn Gln Gly 180 185 190 Ala Val Leu Gln Asp Asn Phe Gly Gln Leu Glu Glu Asn Phe Leu Ser 195 200 205 Ser Ser Cys Gln Ser Gly Tyr Glu Glu Glu Ala Ala Gly Leu Thr Val 210 215 220 Asp Thr Glu Ser Arg Glu Leu Asp Ser Glu Phe Glu Asp Leu Ala Ser 225 230 235 240 Asp Val Arg Ala Gln Asn Glu Phe Lys Asp Glu Ala Gln Ser Leu Ser 245 250 255 His Ser Pro Lys Arg Val Pro Thr Thr Leu Ser Ile Lys Pro Leu Gly 260 265 270 Ala Ile Ser Pro Val Leu Asn Arg Lys Leu Ala Val Gly Ser His Pro 275 280 285 Leu Pro Pro Lys Ile Gln Ser Lys Asp Gly Asn Lys Pro Pro Pro Leu 290 295 300 Lys Thr Ser Glu Ile Thr Asp Pro Ala Gln Val Ser Lys Pro Thr Gln 305 310 315 320 Gly Ser Ala Phe Lys Pro Pro Val Pro Pro Arg Pro Gln Ala Lys Val 325 330 335 Pro Leu Pro Ser Ala Asp Ala Pro Asn Gln Ala Glu Pro Asp Val Leu 340 345 350 Val Glu Lys Pro Glu Lys Val Val Pro Pro Pro Leu Val Asp Lys Ser 355 360 365 Ala Glu Lys Gln Ala Lys Asn Val Asp Ala Ile Asp Asp Ala Ala Ala 370 375 380 Pro Lys Gln Phe Leu Ala Lys Gln Glu Val Ala Lys Asp Val Thr Ser 385 390 395 400 Glu Thr Phe Cys Pro Thr Lys Asp Ser Ser Asp Asp Arg Gln Thr Trp 405 410 415 Glu Ser Ser Glu Ile Leu Tyr Arg Asn Lys Leu Gly Lys Trp Thr Arg 420 425 430 Thr Arg Ala Ser Cys Leu Phe Asp Ile Glu Ala Cys His Arg Tyr Leu 435 440 445 Asn Ile Ala Leu Trp Cys Arg Asp Pro Phe Lys Leu Gly Gly Leu Ile 450 455 460 Cys Leu Gly His Val Ser Leu Lys Leu Glu Asp Val Ala Leu Gly Cys 465 470 475 480 Leu Ala Thr Ser Asn Thr Glu Tyr Leu Ser Lys Leu Arg Leu Glu Ala 485 490 495 Pro Ser Pro Lys Ala Ile Val Thr Arg Thr Ala Leu Arg Asn Leu Ser 500 505 510 Met Gln Lys Gly Phe Asn Asp Lys Phe Cys Tyr Gly Asp Ile Thr Ile 515 520 525 His Phe Lys Tyr Leu Lys Glu Gly Glu Ser Asp His His Val Val Thr 530 535 540 Asn Val Glu Lys Glu Lys Glu Pro His Leu Val Glu Glu Val Ser Val 545 550 555 560 Leu Pro Lys Glu Glu Gln Phe Val Gly Gln Met Gly Leu Thr Glu Asn 565 570 575 Lys His Ser Phe Gln Asp Thr Gln Phe Gln Asn Pro Thr Trp Cys Asp 580 585 590 Tyr Cys Lys Lys Lys Val Trp Thr Lys Ala Ala Ser Gln Cys Met Phe 595 600 605 Cys Ala Tyr Val Cys His Lys Lys Cys Gln Glu Lys Cys Leu Ala Glu 610 615 620 Thr Ser Val Cys Gly Ala Thr Asp Arg Arg Ile Asp Arg Thr Leu Lys 625 630 635 640 Asn Leu Arg Leu Glu Gly Gln Glu Thr Leu Leu Gly Leu Pro Pro Arg 645 650 655 Val Asp Ala Glu Ala Ser Lys Ser Val Asn Lys Thr Thr Gly Leu Thr 660 665 670 Arg His Ile Ile Asn Thr Ser Ser Arg Leu Leu Asn Leu Arg Gln Val 675 680 685 Ser Lys Thr Arg Leu Ser Glu Pro Gly Thr Asp Leu Val Glu Pro Ser 690 695 700 Pro Lys His Thr Pro Asn Thr Ser Asp Asn Glu Gly Ser Asp Thr Glu 705 710 715 720 Val Cys Gly Pro Asn Ser Pro Ser Lys Arg Gly Asn Ser Thr Gly Ile 725 730 735 Lys Leu Val Arg Lys Glu Gly Gly Leu Asp Asp Ser Val Phe Ile Ala 740 745 750 Val Lys Glu Ile Gly Arg Asp Leu Tyr Arg Gly Leu Pro Thr Glu Glu 755 760 765 Arg Ile Gln Lys Leu Glu Phe Met Leu Asp Lys Leu Gln Asn Glu Ile 770 775 780 Asp Gln Glu Leu Glu His Asn Asn Ser Leu Val Arg Glu Glu Lys Glu 785 790 795 800 Thr Thr Asp Thr Arg Lys Lys Ser Leu Leu Ser Ala Ala Leu Ala Lys 805 810 815 Ser Gly Glu Arg Leu Gln Ala Leu Thr Leu Leu Met Ile His Tyr Arg 820 825 830 Ala Gly Ile Glu Asp Ile Glu Thr Leu Glu Ser Leu Ser Leu Asp Gln 835 840 845 His Ser Lys Lys Ile Ser Lys Tyr Thr Asp Asp Thr Glu Glu Asp Leu 850 855 860 Asp Asn Glu Ile Ser Gln Leu Ile Asp Ser Gln Pro Phe Ser Ser Ile 865 870 875 880 Ser Asp Asp Leu Phe Gly Pro Ser Glu Ser Val 885 890 13 20 DNA Artificial Sequence Description of Artificial SequenceT3 13 aattaaccct cactaaaggg 20 14 22 DNA Artificial Sequence Description of Artificial SequenceT7 14 gtaatacgac tcactatagg gc 22 15 22 DNA Artificial Sequence Description of Artificial SequenceKU-GB-2 Sense Primer 15 agagcgacct tgagaccaga aa 22 16 22 DNA Artificial Sequence Description of Artificial SequenceKU-GB-2 Antisense Primer 16 acacaaggca ggagatggaa gt 22 17 20 DNA Artificial Sequence Description of Artificial SequenceKU-GB-5 Sense Primer 17 aaaactcgcc tttctgaacc 20 18 20 DNA Artificial Sequence Description of Artificial SequenceKU-GB-5 Antisense Primer 18 agcaagtaac tggagaagca 20 19 25 DNA Artificial Sequence Description of Artificial SequenceBeta-actin Sense Primer 19 gtcgacaacg gctccggcat gtgca 25 20 25 DNA Artificial Sequence Description of Artificial SequenceBeta-actin Antisense Primer 20 ggatcttcat gaggtagtca gtcag 25 

1. A method for preparing a glioma antigen and/or a glioma antigen gene comprising the following processes: (1) A process of constructing λ phage cDNA library comprising the steps of: total RNA is extracted and purified from a glioma cell line; cDNA is synthesized with the purified mRNA, and this cDNA is introduced into λ phage vector to infect E. coli; (2) A process of generating a reactive serum by eliminating reactants after applying the extract of E. coli to the diluted serum of a glioma patient; (3) A process of detecting positive clones which are reacted by an antibody in the serum by using a labeled anti-IgG antibody after applying the aforementioned λ phage cDNA library to the reactive serum; (4) A process of confirming antibody-reactivity after repeating several screenings for the detected positive clones; (5) A process of a serum screening using the antigens isolated from the positive clones together with at least the sera of glioma patients and healthy persons.
 2. A diagnostic drug for detecting glioma comprising an antibody which specifically binds to whole or part of one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or glioma antigen genes as described in claim 1, and/or to whole or part of said glioma antigens.
 3. A detecting and diagnostic probe for glioma comprising whole or part of antisense strand of DNA or RNA encoding one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or glioma antigen genes as described in claim
 1. 4. An anti-tumor agent with an antibody specifically binding to whole or part of one or more types of glioma antigens obtained by the method for preparing glioma antigens and/or a glioma antigen genes described in claim 1, and/or to whole or part of said glioma antigens as an effective ingredient.
 5. DNA encoding the following protein (a) or (b). (a) A protein comprising the amino acid sequence shown by SEQ ID NO:2; (b) A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, and which has the immunity-inducing activity.
 6. DNA comprising the base sequence shown by SEQ ID NO:1 or its complementary sequence and part or whole of these sequences.
 7. DNA which hybridizes under a stringent condition with DNA of claim 6, and which encodes a protein having the immunity-inducing activity.
 8. DNA encoding the following protein (a) or (b). (a) A protein comprising the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10; (b) A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10, and which has the immunity-inducing activity.
 9. DNA comprising the base sequence shown by SEQ ID NO:3, 5, 7, or 9, or its complementary sequence and part or whole of these sequences.
 10. DNA which hybridizes under a stringent condition with DNA of claim 9, and which encodes a protein having the immunity-inducing activity.
 11. DNA encoding the following protein (a) or (b). (a) A protein comprising the amino acid sequence shown by SEQ ID NO:12; (b) A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:12, and which has the immunity-inducing activity.
 12. DNA comprising the base sequence shown by SEQ ID NO:11 or its complementary sequence and part or whole of these sequences.
 13. DNA which hybridizes under a stringent condition with DNA of claim 12, and which encodes a protein having the immunity-inducing activity.
 14. A protein comprising the amino acid sequence shown by SEQ ID NO:2.
 15. A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:2, and which has the immunity-inducing activity.
 16. A protein comprising the amino acid sequence shown by SEQ ID NO:4, 6, 8, or
 10. 17. A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:4, 6, 8, or 10, and which has the immunity-inducing activity.
 18. A protein comprising the amino acid sequence shown by SEQ ID NO:12.
 19. A protein which comprises an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID NO:12, and which has the immunity-inducing activity.
 20. A peptide comprising a partial protein of any of claims 14 to 19, and which has the immunity-inducing activity.
 21. A fusion protein or a fusion peptide wherein the protein of any of claims 14 to 19 or the peptide of claim 20, and a marker protein and/or a peptide tag, are bound.
 22. An antibody against the protein of any of claims 14 to 19 or the peptide of claim
 20. 23. A host cell comprising an expression system capable of expressing the protein of any of claims 14 to 19 or the peptide of claim
 20. 24. A non-human animal whose gene function to encode the protein of any of claims 14 to 19 or the peptide of claim 20 is deficient on its chromosome, or which over-expresses the protein of any of claims 14 to 19 or the peptide of claim
 20. 25. A screening method for a promoter or a suppressor for the immunity-inducing activity wherein the immunity-inducing activity in T cell is measured and assessed by using the protein of any of claims 14 to 19 or the peptide of claim 20, a test substance, and T cell. 